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ABSTRACT
Introduction: The revised Ghent nosology presents the classical features of Marfan syndrome. However,
behind its familiar face, Marfan syndrome hides less well-known features.
Areas covered: The German Marfan Organization listed unusual symptoms and clinical experts reviewed
the literature on clinical features of Marfan syndrome not listed in the Ghent nosology. Thereby we
identified the following features: (1) bicuspid aortic valve, mitral valve prolapse, pulmonary valve prolapse,
tricuspid valve prolapse, (2) heart failure and cardiomyopathy, (3) supraventricular arrhythmia, ventricular
arrhythmia, and abnormal repolarization, (4) spontaneous coronary artery dissection, anomalous coronary
arteries, and atherosclerotic coronary artery disease, tortuosity-, aneurysm-, and dissection of large and
medium-sized arteries, (5) restrictive lung disease, parenchymal lung disease, and airway disorders, (6)
obstructive- and central sleep apnea, (7) liver and kidney cysts, biliary tract disease, diaphragmatic hernia,
and adiposity, (8) premature labor, and urinary incontinence, (9) myopathy, reduced bone mineral density,
and craniofacial manifestations, (10) atrophic scars, (11) caries, and craniomandibular dysfunction, (12)
headache from migraine and spontaneous cerebrospinal fluid leakage, (13) cognitive dysfunction, schizo-
phrenia, depression, fatigue, and pain, (14) and activated fibrinolysis, thrombin, platelets, acquired von
Willebrand disease, and platelet dysfunction.
Expert commentary: Future research, nosologies, and guidelines may consider less well-known fea-
tures of Marfan syndrome.
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The far side of the Moon is the hemisphere of the Moon that
always faces away from Earth. People call this side ‘the dark
side’, and many artists have let this side stand for the
hidden and the hideous. In contrast, planetary scientists
explain the phenomenon of a hidden side of the Moon by
tidal locking, where tidal forces on Earth slowed down the
rotation of the Moon to the point where always the same
side of the Moon was facing Earth. Today, thanks to science
and discovery, we know that this far side indeed looks
different from the near side of the Moon, but that this far
side also receives sunlight.
Today, the Marfan syndrome has a near side as well. Soon
after the French pediatrician Antoine Bernard-Jean Marfan
(1858–1942) described a combination of symptoms in the 5-
year-old Gabrielle, the picture of this bright side came into life
[1,2]. Marfan himself described dolichocephaly, long limbs,
fingers and toes and contractures of the joints. Pieper and
Irvine-Jones described the syndrome as a congenital cardio-
vascular disease [3], Börger [4] and in another paper on the
same individual, von Pfaundler [5], added ectopia lentis and
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high-grade myopia to the list of features. Weve described the
autosomal dominant trait of inheritance [6], Jequier added
pneumothorax [7], Etter and Glover aortic dissection [8], and
soon thereafter other cardiovascular features such as dilata-
tion of the pulmonary artery, and mitral valve prolapse were
added (for detailed review see [9]). McKusick postulated a
defect of the connective tissue as the cause of the disease
[10], which was confirmed more than 30 years later when Lynn
Sakai’s group identified fibrillin as the specific fibril that was
affected by Marfan disease [11]. Shortly thereafter, Dietz and
colleagues reported the first pathogenic variant in the fibrillin1
gene [12]. Various systematic descriptions and nosologies con-
firmed and further elaborated this picture of Marfan syndrome
which today forms a familiar face and well-known side of
Marfan syndrome.
However, as in planetary science, medical science moves on to
explore the far side of the Marfan syndrome. Today, this far side
may indeedhave a ‘dark’ face tomanypatients andphysicians. The
disease may hide something unknown and poorly described that
threatens the affected patients and that takes by surprise the
physicians who are not prepared appropriately. For this article,
we asked patient representatives about their less usual experi-
ences with the Marfan syndrome, and we sampled a team of
well-known experts to take a trip to the dark side of Marfan
syndrome. We evaluated huge fields of literature reporting unfa-
miliar features of Marfan syndrome, which we sampled and
mapped carefully to present it in this review. In thisway,we sought
to encourage future investigations. Further, we made some pre-
liminary conclusions on the refinement of diagnostic routines in
the medical care for patients with Marfan syndrome.
2. Methods
In a first step, we asked the German Marfan Organization to
compile a list of unusual symptoms and complaints among their
members and other people seeking their advice (see ‘the patients’
perspective’ for further description; Table 1). At the same time, by
mid-2017, the first and the senior author of this article launched an
extensive analysis of Medline with ‘Marfan syndrome’ as key word
to search for features or symptoms of Marfan syndrome that were
not listed in any of the three international nosologies of Marfan
syndrome. This search yielded about 6,200 original articles includ-
ing case reports. Our search was qualitative in nature, where we
intended only to pick up reports of unusual manifestations and
symptoms of Marfan syndrome. This search yielded a list of 259
original publications, which we used to derive distinct clusters of
manifestations and symptoms. We present the results of our initial
Medline search in Table 2. In a next step, we set up a list of clinical
scientists, whom we considered as leading experts in the respec-
tive cluster of clinical features. All experts whomwe invited agreed
to contribute. We provided our table of literature (Table 2), and
asked each expert to repeat the literature search on their respec-
tive cluster of clinical features and to perform an in depth analysis
of the cited literature topresent their viewon the scopeandclinical
relevance of distinct organ system features.We asked all experts to
provide their opinion on the clinical and diagnostic consequences
of these features. In a final step, we compiled a final list of organ
features. The first and the senior author used a Likert scale to
quantify their evaluative estimation of the scientific and clinical
significance of each feature of Marfan syndrome (Figure 1) [13]. In
addition, we asked all experts to comment on patients’ reported
symptoms in their respective organ chapter.
Finally, all potential features of Marfan syndrome may also
occur in other genetically caused thoracic aortic syndromes such
as Loeys-Dietz syndrome or in vascular Ehlers-Danlos syndrome.
Therefore, we provide a separate table, where we list all clinical
features along with the first and senior authors’ evaluative opinion
on the association of these features with the respective syndrome.
To support our evaluation, we screened Medline for the presence
of these features, where we combined the search term ‘Loeys-
Dietz syndrome’, or ‘Ehlers-Danlos syndrome vascular type’,
respectively, with a clinical feature as the other search term,
respectively. We display in Table 3 all original publications includ-
ing case reports that we found informative on the occurrence of
clinical features in Loeys-Dietz or vascular Ehlers-Danlos syndrome
(Table 3).
3. The patients’ perspective by Marina Vogler
Authors of this article asked me as a patient representative of the
GermanMarfanorganization to report,what patientswithMarfan
syndrome experience as features on the ‘dark side’ of the Marfan
syndrome. We defined as ‘dark side’ what we experience quite
often as symptoms and features which we think may belong to
the Marfan syndrome, but which do not show up in official
descriptions of the syndrome or in official patient guides
[14,15], and which are usually not routinely checked for by med-
ical experts of the Marfan syndrome. We present a list of symp-
toms and complaints, which we derived from three sources: First,
from notes that we took over many years during our telephone
counseling sessions with members of our organization, or other
people from the general German population telling us that they
hadMarfan syndrome. Second, from information collected froma
Marfan-Facebook-group survey that we started from Friday 29th
to Sunday, 31st October 2018. Third, from asking our members
and visitors with Marfan syndrome on our official ‘23rd German
Article highlights
We performed a review of clinical features of the Marfan syndrome
that are not listed in the Ghent nosology. This review yielded the
following major results:
● Patients report symptoms and complaints that experts may not have
in their focus of study and research.
● Bicuspid aortic valve, aneurysm of the cerebral arteries, cognitive
dysfunction, and schizophrenia may be removed from the list of
potential manifestations of the Marfan syndrome.
● Tricuspid valve prolapse, cardiomyopathy, sleep apnea, vascular dis-
ease of the aortic branching vessels, and liver and kidney cysts
emerge as manifestations of the Marfan syndrome.
● Heart failure, supraventricular and ventricular arrhythmia, restrictive
lung disease, headache, fatigue, and chronic pain are features that
complicate the natural or medical course of Marfan syndrome.
● The image of Marfan syndrome as a whole is in transition from a
monogenetic disease of isolated organ system involvement (‘multi-
systemic’) of the young and slender to a multifactorial generalized
atherosclerotic and degenerative (‘generalized’) disease of the older
and obese.
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Marfan Day’, held in Fulda, 4 May 2019. We graded reported
complaints as ‘major’ whenever these were mentioned by more
than 5 independent individuals, and ‘minor’, whenever men-
tioned less often (Table 1).
4. Valvular features by Yskert von Kodolitsch and
Evaldas Girdauskas
4.1. Aortic valve disease
Aortic valve disease presents as an integral part of the well-
described aortic root disease in Marfan syndrome. Therefore,
aortic valve regurgitation, caused by dilatation of aortic valve
annulus and the sinotubular junction, in combination with
aortic valve cusp prolapse, and frequently aortic valve cusp
commissural fenestrations are well-described features of
Marfan syndrome that already have their established place
on the bright side of clinical attention. However, there is an
emerging discussion on the causal relationship of Marfan
syndrome and the congenitally bicuspid aortic valve. The
classical view sees both entities as differential diagnosis of
alternative causes of aneurysmal formation in the proximal
aorta [16]. Most advocators of this view emphasize that aneur-
ysms in Marfan syndrome are located primarily in the sinuses
of Valsalva, whereas aneurysms in bicuspid aortic valve tend to
be located in the ascending aorta beyond the sinotubular
junction [17,18]. The opposing view holds, that a congenitally
bicuspid aortic valve is an integral part of the Marfan syn-
drome. Advocators of this view describe an increased fre-
quency of 4.5–4.7% of the bicuspid aortic valve in Marfan
Table 1. Patients‘ symptoms reported by the German Marfan Organization.
Patients complaints*
Major Minor
Valvular features (chapter 4)
None None
Myocardial features (chapter 5)
None None
Electrophysiologiscal features (chapter 6)
None Tachycardia
Aortic branching vessels (chapter 7)
None Hypotension especially in adolescence
Syncope especially in adolescence
Lung features (chapter 8)
None None
Sleep physiology (chapter 9)
None None
Abdominal features (chapter 10)
Renal cysts Gastritis
Hepatic cysts Splenic cysts
Gastric complaints Canker sores
Intestinal complaints
Urogenital features (chapter 11)
Bladder problems Incontinence
Urinary tract infection Maldescensus testis
Pregnancy with premature labor Ovarian Cysts
Kidney stones
Musculo-skeletal features (chapter 12)
Otitis media Deviated nasal septum including surgical correction in adolescence
Sinusitis Recurrent infections including angina tonsillitis, otitis media, sinusitis
Hemangioma of thoracic vertebral body
Ingrown nails of the big toe
Manifest osteoporosis
Pelvic tilt
Dermatological features (chapter 13)
Psoriasis (located only on the head) Plantar soft tissue tumors, sometimes with necrotizing
Dry, scaly skin
Dental features (chapter 14)
Dental roots that are elongated, or wondrous, or elongated
bending upward or downward
Dental enamel problems
Gum bleeding
Headache as neurological feature (chapter 15)
Headache
Migraine
Psychological features (chapter 16)
Autism Developmental delay
Asperger syndrome
Attention Deficit Syndrome (ADS)
Joint pain
Hemostatic features (chapter 17)
None Recurrent thrombosis
Coagulation disease
Eye features (chapter 18)
Early onset cataract Prolonged conjunctival wound healing
*We considered symptoms major with frequent mentioning, and minor with clearly less frequent mentioning.
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syndrome, and even 6.8–8.5% in pediatric Marfan patients
[19,20], compared to 0.5–1.5% BAV prevalence in the general
population. It is argued that common pathogenic mechanisms
are likely to underlie both entities [21,22]. However, in a larger
population of Marfan patients, the prevalence of bicuspid
aortic valve was 1.8% [23], which compares well to the
prevalence in the general population. Irrespective of the cau-
sal unity, the coexistence of both entities appears to relate to a
more pronounced aortic disease [21–23]. A third view, which
we call the differentiated view, identifies a subgroup of bicus-
pid aortic valve disease with aneurysm located in the sinuses
of Valsalva (so-called bicuspid root-phenotype), which mimics
Figure 1. Evaluative estimation of the clinical significance of suggested features of the Marfan syndrome.
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the aneurysmal pattern of the Marfan syndrome. This bicuspid
aortic valve subtype lacks other clinical features of the Marfan
syndrome, but it shares some of its pathogenic and genetic
features. Such aortic phenotypes have been described for
decades in conjunction with, but also independently of their
etiology, as ‘annuloaortic ectasia’ [24], or as ‘forme fruste’ of
Marfan syndrome [25], Today, this bicuspid aortic phenotype
has been associated with nucleotide sequence variants in the
FBN1 gene [26,27], but also with other genes known to cause
genetic aortic diseases [27].
In conclusion, we consider bicuspid aortic valve disease as a
distinct cause of aortic aneurysm. Bicuspid aortic valve may
coincide with Marfan syndrome and thereby aggravates the
proximal aortic aneurysmal disease. There is an aortic pheno-
type of bicuspid aortic valve disease that we call the ‘bicuspid
root-phenotype’, which represents most probably a congenital
Table 2. Initial Medline search for features or symptoms of Marfan syndrome.
Cluster Organ Organ involvement Number of publications*
1 Heart valves
Mitral valve prolapse 4
Tricuspid valve prolapse 13
Bicuspid aortic valve 3










Cerebral artery aneurysm 17
Visceral arteries 3
Tortuosity or aneurysm of medium sized arteries 11
7 Atherosclerosis
Cardiovascular risk factors 5
Atherosclerotic disease/Coronary artery disease 1
4 Sleep-disordered breathing






































*The specific references are available as supplementary data.
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Table 3. Association of feature with syndrome.
Association of feature with syndrome Number of publications*
Chapter Suggested features of MFS MFS LDS vEDS LDS vEDS
4 Valvular features
Bicuspid aortic valve - + - 6 1
Mitral valve prolapse +++ ++ + 15 8
Pulmonary valve prolapse/regurgitation ++ 2 1
Tricuspid valve prolapse +++ + - 1
5 Myocardial features
Heart failure + + - 7 2
Cardiomyopathy +++ + - 2 2
6 Electrophysiological features
Supraventricular arrhythmia + + - 4
Ventricular arrhythmia ++ + - 2 1
Abnormal repolarization + + - 1
7 Aortic branching vessels
Coronary Artery Disease
Spontaneous coronary artery dissection ++ ++ +++ 4 11
Anomalous coronary arteries + + - 4 1
Atherosclerotic coronary artery disease - - -
Other aortic branching vessels
Tortuosity, aneurysm, and dissection +++ +++ +++ 2 1
Cerebral/carotid arteries ++ +++ ++ 11 1
Visceral arteries ++ +++ +++ 2 10
Spontaneous cervical artery dissection ++ ++ +++ 3 18
8 Lung features
Restrictive lung disease ++ + - 1
Parenchymal lung disease ++ - - 3 1
Airway disorders ++ + - 1
9 Sleep physiology features
Obstructive sleep apnea +++ ++ - 1 6
Central sleep-apnea ++ -
10 Abdominal features
Liver and kidney cysts +++ - 1
Biliary tract features - - - 1
Diaphragmatic hernia ++ ++ + 3
Adiposity +++ -
11 Urogenital features
Preterm labor - + +++ 1 3
Urinary incontinence + - 1 7
12 Musculo-skeletal features
Myopathy ++ ++ ++ 2
Reduced bone mineral density ++ + + 1 1
Craniofacial manifestations +++ +++ +++ 3
13 Dermatological features
Atrophic scars ++ ++ +++ 1
14 Dental features
Caries + + 1 5
Craniomandibular dysfunction +++ +++ +++ 3
15 Headache
Migraine + + + 1 2
Spontaneous cerebrospinal fluid leakage +++ ++ - 1 4
16 Psychological features
Cognitive dysfunction - + - 3 2
Schizophrenia - - -
Depression + + +
Fatigue ++ ++ ++ 2
Pain +++ +++ +++ 1
17 Hemostatic features
Activated fibrinolysis, thrombin, platelets + + + 4
Acquired von Willebrand disease type 2a 1
Platelet dysfunction 1 3
MFS identifies Marfan syndrome; LDS, Loeys-Dietz syndrome; and vEDS, vascular type of Ehlers-Danlos syndrome.
We grade the strength of association of a respective feature with a respective syndrome as -, with no association with the respective syndrome; +, likely association,
++, strong association; +++, as very strong association.
*The specific references are available as supplementary data.
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type of bicuspid aortopathy and is associated with mutations
in various genes, while some of them are known to cause
specific genetic aortic syndromes such as Marfan syndrome.
4.2. Mitral valve disease
In Marfan syndrome, severe myxomatous mitral valve prolapse
usually coexists with aortic root aneurysm. However, mitral valve
prolapse and mitral valve regurgitation were listed as indepen-
dent diagnostic features of Marfan syndrome already in the first
international nosology of heritable disorders of connective tis-
sue, established in September 1986, in Berlin [28]. Since then,
subsequent revisions of this nosology, first in 1996 and then in
2010, both in Ghent, corroborated the independent diagnostic
importance of mitral valve prolapse for the diagnosis of Marfan
syndrome [16,29]. Therefore, it may appear surprising that we
include mitral valve disease into the list of dark side features of
the Marfan syndrome. The reasons are the following: First, com-
pared to the studies on aortic disease, the data on mitral valve
disease in Marfan syndrome are rather scarce. Second, most
available studies had been performed in the last millennium,
and were often based on today outdated echocardiographic
technology including M-Mode, outdated diagnostic criteria of
mitral valve prolapse, and in subjects diagnosed with Marfan
syndrome using obsolete diagnostic criteria of the syndrome.
Finally, classical studies focused on specific clinical subgroups,
so-called neonatal Marfan syndrome, children, adults, or
included only surgical patients, and carried thereby substantial
patient selection bias [30–38].
Here, we summarize the clinical profile of mitral valve dis-
ease in Marfan syndrome based on data that utilized modern
diagnostic criteria of mitral valve prolapse, current 2-dimen-
sional echocardiographic technology, and Ghent criteria of
Marfan syndrome [29], including demonstration of a patho-
genic FBN1 variant, without any age limitations. The first large
population-based cohort study using these criteria included
204 patients and reported the following findings [39]:
(1) Mitral valve prolapse is an age-dependent manifesta-
tion of Marfan syndrome, where the estimated cumula-
tive distribution of mitral valve prolapse is 8.7% at 1
year of age, 26.7% at 10 years, 36.1% at 20 years, 42.6%
at 30 years, 47.7% at 40 years, 51.8% at 50 years, and
60.8% at 80 years of age.
(2) Severe mitral valve regurgitation is also age-dependent,
with an estimated cumulative distribution of 0 at 1 year,
2.5% at 20 years, 13.3% at 40 years, 32.7% at 60 years,
and 55.8% at 80 years of age.
(3) Infective endocarditis of the mitral valve has an esti-
mated cumulative probability of <1% up to the age of
30 years, but then increases rapidly up to almost 20% at
the age of 80 years.
(4) Mitral valve prolapse is associated with dural ectasia,
ectopia lentis, and skeletal involvement.
(5) Severe mitral valve regurgitation is related to tricuspid
valve prolapse and to the sporadic form of Marfan
syndrome.
Another population-based cohort study of 112 patients with
Marfan syndrome and the criteria of mitral valve prolapse
established clinical predictors of mitral valve complications
[40]. The progression of mitral valve regurgitation of ≥1
grade was independently associated with flail mitral leaflet,
and increased indexed end-systolic left ventricular diameters.
Clinical adverse events of the mitral valve including endocar-
ditis, heart failure, and mitral valve surgery correlated signifi-
cantly with a flail mitral leaflet and mild or moderate degree of
mitral valve regurgitation. Aortic dilatation, dural ectasia, and
sporadic mode of inheritance were not associated with out-
come [40].
Finally, a cohort study of 116 patients with a causative FBN1
gene mutation and ≤moderate mitral valve regurgitation at
baseline examined the impact of FBN1 gene mutation char-
acteristics. This study found only a marginal relationship
between FBN1 gene mutations (i.e., located both in a trans-
forming-growth-factor beta-binding protein-like (TGFb-BP)
domain and in the calcium-binding epidermal growth factor-
like (cbEGF) domain) and the risk of mitral valve surgery [41].
In contrast to mitral valve prolapse alone, moderate mitral
valve regurgitation was related to both ventricular premature
complexes >10/h, and to ventricular couplets, or non-sustained
ventricular arrhythmia in adults with Marfan syndrome, whereas
both failed to predict ventricular tachycardia events [42].
Premature calcification of mitral valve ring was present in
only one of 138 adults with Marfan syndrome (0.7%) [43]. Such
calcification was previously considered as a diagnostic sign of
Marfan syndrome [29], but has been eliminated from the list of
Marfan signs in the recent nosology [9,16]. Given the preva-
lence of mitral valve prolapse in 31.7% pediatric Marfan
patients, it was considered important for an early diagnosis
of Marfan syndrome in children [19]. In some children with
severe variants of Marfan syndrome, such as neonatal forms,
or de-novo mutations of the FBN1 gene, severe valvular dis-
ease may occur with increased frequency.
In conclusion, mitral valve prolapse is an age-dependent
manifestation of the Marfan syndrome, with clinical conse-
quences of mitral valve regurgitation and endocarditis that
usually progress with an increasing age.
4.3. Pulmonary valve disease
Dilatation of the main pulmonary artery, ‘in the absence of
valvular or peripheral pulmonic stenosis, before the age of 40
years’ was a diagnostic criterion of Marfan syndrome in the
first Ghent nosology, but it was removed from the list of
diagnostic signs [44] in the revised nosology due to the lack
of diagnostic specificity [16,29]. The prevalence of pulmonary
artery dilatation ranges between 8% and 16% in children
[20,45] and 37% and 74% in adults with Marfan syndrome
[20,44,46]. In addition, the pulmonary valve was shown to
exhibit echocardiographic signs of cusp prolapse in 6% chil-
dren and in 4% adults with Marfan syndrome, as well as of
mild pulmonary regurgitation in 11% children, and 6% adults
with Marfan syndrome [47]. Therefore, surgeons tend to
assume pulmonary root disease in Marfan syndrome that
leads them to dissuade a Ross procedure in Marfan syndrome
EXPERT REVIEW OF CARDIOVASCULAR THERAPY 889
[48,49]. However, main pulmonary artery aneurysms >6 cm
diameter as an isolated indication for elective surgery [44], or
more than mild pulmonary regurgitation occurs only excep-
tionally in Marfan syndrome [20]. In conclusion, the pulmonary
artery root may be affected by the same connective tissue
defect as the aortic root in Marfan syndrome. However, clinical
consequences of pulmonary root disease are rare and may
occur only with increased pulmonary artery pressure.
4.4. Tricuspid valve disease
Tricuspid valve disease was almost completely disregarded as
a manifestation of the Marfan syndrome. However, tricuspid
valve prolapse appears to be quite common in Marfan syn-
drome, a finding which emerged from some more recent
studies:
(1) The overall prevalence of tricuspid valve prolapse was
22% in a cohort of 204 individuals with Marfan syn-
drome of all ages. With 4% in the first decade of life,
17% in the second, 29% in the third, 32% in the fourth
decade, there appeared to be a slight increase of the
prevalence of tricuspid valve prolapse in the first half of
life. However, the prevalence appeared to be lower in
the second half of life, where the prevalence was 24%
in the fifth, 15% in the sixth, and 0% beyond the sixth
decade of life [39].
(2) Tricuspid valve prolapse presents with echocardio-
graphic features of valvular thickening and prolapse
with chordal elongation which involves all 3 leaflets.
Histologic examination revealed findings consistent
with valvular thickening and myxomatous degenera-
tion [50].
(3) Concurrent involvement of the mitral and the tricuspid
valves appears to be common in Marfan syndrome [50].
(4) Progression of the severity from mild to moderate or
severe regurgitation occurs only in a small fraction of
affected individuals [19].
In addition to tricuspid valve degenerative process, myopathy
involving also the right ventricle may at least in theory, be
another alternative mechanism which may lead to tricuspid
valve regurgitation [51]. In conclusion, tricuspid valve disease
although neglected, is common and potentially harmful in
Marfan syndrome.
4.5. Expert opinion on patients’ reported symptoms
(Table 1)
We see two reasons why patients do not report ‘valve-related
problems’ (Table 1). First, valve dysfunction results in heart
failure or heart arrhythmia, and then patients may report these
symptoms instead of valve dysfunction. Second, fortunately,
both heart failure and arrhythmia do not occur often in Marfan
syndrome, and if they occur, they usually will lead the patient
to a cardiologist who will identify valve dysfunction and pro-
vide adequate therapy. Therefore, symptoms of valvular heart
failure do not occur often, and if they occur, these symptoms
will be usually treated effectively soon.
4.6. Conclusion
Marfan syndrome is a systemic disease of all heart valves,
where the left-sided valves account for the majority of clinical
symptoms, in an age-dependent manner. However, the right-
sided valves are commonly affected by the same tissue dis-
ease, and therefore should be similarly included in the clinical
surveillance and decision-making process.
5. Myocardial features by Julie De Backer
5.1. Heart failure
In several (historical) series on death in Marfan syndrome,
heart failure is mentioned as one of the leading causes.
Figures vary between 5% and 30% which puts heart failure
at least at the same level as aortic dissection [52,53]. In addi-
tion, there are several reports on end-stage heart failure
necessitating heart transplantation in patients with Marfan
syndrome. The known problems of both aortic valve regurgi-
tation due to aortic root dilatation and important mitral valve
regurgitation in the setting of valve prolapse are often the
cause of this heart failure [54].
5.2. Marfan cardiomyopathy
In addition, several reports from independent researchers
have been published in recent years indicating a primary
intrinsic dysfunction of the myocardium in Marfan syndrome.
The reported prevalence of what is now addressed as ‘Marfan
cardiomyopathy’ ranges from 3% to 68% across different ser-
ies [54,55], depending on the definition and population char-
acteristics. Involvement of both left and right ventricles with
systolic and diastolic dysfunction has been described [56–62].
In the majority of cases, dysfunction is mild, with subclinical
abnormalities that do progress much over time. Although it
has not yet been clearly demonstrated, a link between such
mild intrinsic cardiomyopathy and an unfavorable course in
the event of an additional hemodynamic trigger such as valve
dysfunction and/or aortic root replacement is not unlikely.
Studies in mouse models of Marfan syndrome suggest such
a relationship, where the application of pressure overload due
to partial ligation of the aortic arch leads to clear cardiomyo-
pathy [63]. These models suggest mechanosignaling as a pos-
sible cause for cardiomyopathy [64]. The presence of fibrillin-1
in the myocardium has clearly been evidenced in wild-type
mice, with indications of more abundant amounts in the atria
[65]. It is assumed that the underlying abnormality in the FBN1
gene results in a deficient mechanosignaling function of the
fibrillin microfibrils in the extracellular matrix and that
mechanical factors such as volume- or pressure overload are
inadequately compensated, which in turn leads to myocardial
dysfunction. In recent years, the concept of abnormal mechan-
osignaling has also been introduced in the explanation for
aortic pathology in Marfan syndrome [66].
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Whether the type of underlying pathogenic FBN1 variant
matters in whether or not people are more susceptible to
developing cardiomyopathy is still unclear, but in a small
study, a difference was observed with patients carrying non-
missense variants having more left ventricular dilatation than
patients with missense variants [67].
5.3. Expert opinion on patients’ reported symptoms
(Table 1)
Table 1 does not list classical symptoms of heart failure includ-
ing dyspnea, orthopnea, nycturia, and ankle edema, which is
not surprising since myocardial dysfunction usually remains
mild in Marfan patients. However, according to our experi-
ence, patients with Marfan syndrome and clinically significant
heart failure will present such symptoms.
5.4. Conclusion
Although more extensive studies in the longer term are cer-
tainly necessary to further unravel the clinical relevance of
cardiomyopathy, the findings from human studies and
mouse models, in any case, indicate that we must be vigilant
about this problem. Careful monitoring of myocardial function
and potential consequences such as (severe) heart failure and
arrhythmia in patients with Marfan syndrome is warranted.
6. Electrophysiological features by Anthony
Demolder
Ever since the first report in 1985 by Chen et al., growing
evidence has revealed an elevated risk of arrhythmia in
patients with Marfan syndrome [68]. In both children and
adults, an arrhythmic predisposition for supraventricular as
well as ventricular arrhythmias can be noted, sometimes inde-
pendent from valvular abnormalities [68,69].
6.1. Supraventricular arrhythmia
Among the supraventricular arrhythmias, atrial fibrillation and
Wolff-Parkinson-White syndrome have been described. Atrial
fibrillation is reported to be present in 8% of patients with
Marfan syndrome [69]. In the general population, the preva-
lence of atrial fibrillation is 1% [70], indicating that Marfan
syndrome has an increased prevalence of this arrhythmia. In
contrast, Wolff-Parkinson-White syndrome has only been
described in case reports of Marfan syndrome suggesting a
mere coincidental association [71,72].
6.2. Ventricular arrhythmia
More frequently observed are the ventricular arrhythmias in
Marfan syndrome, as evidenced by multiple studies.
Significant ventricular ectopy defined as >10 premature
ventricular contractions per hour occurs in 20-30%, whereas
non-sustained ventricular tachycardia is shown to be pre-
sent in 10-20% of Marfan syndrome patients [55,69,73].
Three studies report life-threatening arrhythmias in 7-9%
of their patients along with sudden cardiac death most
likely due to arrhythmia occurring in up to 4% [55,69,74].
These numbers indicate that ventricular arrhythmias are an
important cause of death in Marfan syndrome in addition to
aortic dissection or -rupture and heart failure. Studies on
causes of death after aortic root replacement report fatal
arrhythmias in 12-18% of patients with Marfan syndrome,
making it the 2nd most frequent cause of death after sur-
gery of the aorta [52,75]. A possible association with under-
lying intrinsic myocardial dysfunction, as described above,
seems plausible and warrants further investigation.
6.3. Abnormal repolarization
In addition to an arrhythmic predisposition, some reports have
described associations between Marfan syndrome and abnor-
mal repolarization. One study demonstrated prolonged con-
duction times and abnormal repolarization, as evidenced by
longer PQ-intervals, longer QT-intervals, and more ST-segment
depressions compared to controls [73]. In perspective, the PQ-
intervals remained within normal boundaries (<200 ms). In line
with this, current literature holds only case reports on Marfan
syndrome and heart block with no hard evidence regarding an
association [76,77].
In contrast, 16–20% of patients with Marfan syndrome were
reported to have a prolonged QTc-interval (>440 ms) [55,73]
with similar percentages seen in children with Marfan syn-
drome (9-20%) [68,78]. As opposed to the PQ-interval dura-
tion, the QT-interval prolongation was unrelated to the degree
of aortic root dilation, the dimension, and function of the left
ventricle and the presence of valvular prolapse [73]. Extended
prolongation of the QT-interval combined with early after
depolarization can trigger arrhythmia with potentially life-
threatening complications. Based on current evidence, careful
consideration when initiating drugs with pro-arrhythmogenic/
QT prolonging potential seems warranted.
The combination of arrhythmic predisposition along with
abnormal repolarization in Marfan syndrome strongly sug-
gests the presence of an underlying subclinical aberration in
the electrophysiological substrate. To date, the mechanism
underlying these cardiac disorders remains unknown. Most
studies do show an association between left ventricular
dilation, altered repolarization and ventricular arrhythmia
[55,69,73,74]. Valvular disease and cardiovascular surgery,
both frequently encountered in Marfan syndrome, may be
additional contributing factors. In fact, moderate mitral
valve regurgitation was associated with ventricular prema-
ture complexes >10/h, ventricular couplets and non-sus-
tained ventricular tachycardia in adults with Marfan
syndrome [69]. However, both mitral valve prolapse and
mitral valve regurgitation failed to predict ventricular tachy-
cardia events [69].
Attempts at risk stratification have described some deter-
minants, including ventricular ectopy, non-sustained ventricu-
lar tachycardia, ventricular tachycardia, impaired left
ventricular systolic function and elevated serum N-terminal
pro-brain natriuretic peptide (NT-proBNP) levels [74]. Of
these, serum NT-proBNP level was shown to be the strongest
independent predictor of arrhythmogenic events [69,74].
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6.4. Expert opinion on patients’ reported symptoms
(Table 1)
Patient-reported symptoms such as tachycardia or palpitations
may be an indicative feature of both supraventricular and ven-
tricular arrhythmia. Considering the arrhythmic predisposition in
Marfan syndrome, screening tools such as resting ECG and
ambulatory ECG are justified to uncover the presence of arrhyth-
mias, especially in patients reporting suggestive symptoms.
6.5. Conclusion
Since the potential complications are life-threatening arrhyth-
mia and sudden cardiac death, identifying patients at risk is
warranted and a low threshold for arrhythmic follow-up inves-
tigations (e.g., resting ECG, ambulatory ECG, and echocardio-
graphy) is justified.
7. Aortic branch vessels by Shaine Morris and Anji
Yetman
Given that the majority of vascular disease in Marfan syn-
drome is aortic, little attention has been paid to aortic branch
vessels. However, tortuosity, aneurysm, and dissection have
been reported throughout the arterial system.
7.1. Coronary artery disease
In Marfan syndrome, myocardial ischemia most often occurs
secondary to dissection of the aortic root with propagation of
the dissection into the coronary vessels [79], or iatrogenic
postoperative coronary obstruction. Other potential types of
coronary artery disease include: (1) spontaneous coronary
artery dissection, (2) anomalous coronary artery origin and
(3) atherosclerotic coronary artery disease. The three causes
are discussed below.
7.1.1. Spontaneous coronary artery dissection (SCAD)
Although the most common associations with SCAD are cor-
onary atherosclerotic disease, pregnancy/peripartum status,
and fibromuscular dysplasia, some cases of Marfan syndrome
have been described [80–92]. In a population-based study of
SCAD in the United States using administrative records, 10 of
66,360 admissions for SCAD had a co-existing diagnosis of
Marfan syndrome [84]. In a study of 114 cases of SCAD retro-
spectively evaluating for connective tissue disease, 3 were
diagnosed with connective tissue disease, including 1 with
Marfan syndrome and 2 with vascular Ehlers-Danlos syndrome
[82]. Another study of 107 patients with SCAD were prospec-
tively considered for genetic evaluation [93]. Among this
group, no patients with Marfan syndrome were detected, but
3 with COL3A1 variants and 1 with a SMAD3 variant were
diagnosed. Although several case studies reported pathologi-
cal findings consistent with cystic medial necrosis in rare cases
of SCAD, as far as we know, the first patient with a clinical
diagnosis of Marfan syndrome was reported in by Corrado et
al. in 1992 [86,94,95]. The youngest individual to date with
SCAD in Marfan syndrome was in a 12-year-old girl [91].
Medical treatment rather than intervention is often pursued
if possible [90,92]. If intervention is necessary, both percuta-
neous intervention and bypass surgery have been successfully
employed [88,90,91]. Percutaneous intervention can be com-
plicated, and risk of extending the dissection is possible [91].
7.1.2. Anomalous coronary arteries
Multiple case reports [96–101] and one case series [102] note
the presence of anomalous coronary artery origin in associa-
tion with Marfan syndrome. Anomalous right and left coronary
arteries, as well as aberrant origin of the circumflex from the
right coronary artery have been described.
The frequency of this association, and whether this truly
differs from the general population (who may be more apt to
go unrecognized) is unknown. Mulder and colleagues identi-
fied 3 patients with Marfan syndrome who had anomalous
coronary arteries resulting in a prevalence of 5.6%, signifi-
cantly greater than the 1.6% prevalence quoted for the gen-
eral population [102].
Anomalous left coronary artery, and to a lesser extent,
anomalous right coronary artery are recognized causes of
myocardial ischemia and sudden death, particularly in the
presence of an intramural or interarterial coronary course
[103]. The patient with Marfan syndrome presenting with
chest pain or loss of consciousness, invokes concern for aortic
dissection or ventricular arrhythmias [55] and the potential for
ischemic coronary artery disease may be overlooked particu-
larly in the absence of acquired risk factors. A normal CTA or
MRA of the aorta may provide false reassurance regarding a
pathologic cause of chest pain. Evaluation for ischemia may be
warranted, irrespective of acquired risk factors for coronary
artery disease.
Given the need for coronary artery reimplantation at the
time of proximal aortic replacement, the takeoff of the coron-
ary arteries may be important in surgical planning. While
routine MRA or CTA are typically performed to rule out distal
aneurysmal disease prior to surgical aortic root replacement, it
has been suggested that coronary artery CT should addition-
ally be performed in order to rule out anomalous coronaries
[97,102].
Of the three patients described by Mulder et al. all had a
favorable outcome although lack of pre-operative diagnosis
was associated with a major perioperative complication [102].
Echocardiographic and angiographic focused imaging of
the aortic root may result in the finding of coronary anomalies
that might otherwise go unnoticed. Pre-operative coronary
imaging may provide useful information for our surgical col-
leagues. The approach to the patient with an asymptomatic
anomalous left coronary artery who does not yet meet surgical
criteria for aortic root replacement remains uncertain with
regards to whether the timing of surgical intervention for
anomalous left coronary artery should be altered to coincide
with root replacement, or whether root replacement should
be performed at a smaller size to avoid two aortic root
surgeries.
7.1.3. Atherosclerotic coronary artery disease
The frequency of atherosclerotic coronary artery disease in
Marfan syndrome is unknown. Risk factors for atherosclerosis,
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including obesity, smoking, hyperlipidemia, and hypertension
do not differ from the general population [104]. In addition,
carotid intimal thickness, a surrogate measure for coronary
artery disease, has been shown not to differ between Marfan
syndrome and the general population [105]. Together, this
data suggests that patients with Marfan syndrome should
carry the same risk of atherosclerotic coronary artery disease
as those without. The current literature however is devoid of
reports of atherosclerotic coronary artery disease in Marfan
syndrome. Whether this relates to a younger age of death
due to aortic complications (particularly in those with risk
factors for coronary artery disease), underreporting of a less
than novel phenomenon, or an inherent protective mechan-
ism remains unknown. Impaired fibrillin-1 function has been
associated with increased arterial wall stiffness leading to
increased atherosclerotic burden in an ApoE deficient mouse
model [106]. Similarly, elastic fiber fragmentation is associated
with increased plaque rupture and myocardial infarction in
atherogenic mice [107]. While there is an established relation-
ship between increased aortic stiffness and atherosclerotic
burden in humans without Marfan syndrome, the same rela-
tionship has not been documented in patients with Marfan
syndrome. The pleiotropic effects of the cytokine TGFbeta are
poorly understood as they relate to atherosclerosis with both
protective and deleterious effects documented. This raises the
question as to whether TGFbeta may in fact play a beneficial
role in patients with Marfan syndrome. Becker and colleagues
examined the coronaries in five young adults with Marfan
syndrome and death from aortic complications [79]. They
noted the extramural coronaries in all five patients to be
similarly affected to the aorta with elastic lamella fragmenta-
tion in the vascular media. Associated aneurysmal disease of
the extramural coronaries was noted in one of the five
patients [79]. A larger vessel diameter could, in theory, provide
some degree of protection from occlusion from atherosclero-
tic plaque despite the presence of increased vascular stiffness
and elastic fiber fragmentation.
The above-mentioned risk factors for coronary artery dis-
ease have also been implicated in aortic aneurysm formation
and dissection. While patients with Marfan syndrome have
historically been considered to have an asthenic body habitus,
the presence of overweight or obesity was documented to be
present in 26% of an adult patient cohort, a rate not different
than that of the general population [104]. Adipose tissue is
known to be metabolically active with the production of
several different cytokines and vasoactive substances includ-
ing angiotensin II and TGF-beta which can adversely affect
aortic histology and biomechanics [104].
While the risk of atherosclerotic coronary disease remains
undefined in Marfan syndrome, modification of standard risk
factors remains essential to limiting aortic disease [104].
Healthy body weight, normal levels of glycated hemoglobin
(HgbA1C) and fasting lipid profile should remain a focus of
preventative cardiac care. Other established risk factors for
coronary artery disease in the general population and aortic
disease in the Marfan population include elevated homocys-
teine [108–110] and impaired endothelial function [111].
Elevated homocysteine levels can occur secondary to genetic
variants or nutritional deficiency and have been associated
with a significantly greater degree of aortic pathology in
patients with Marfan syndrome [109,110]. Treatment with B
vitamins may improve outcome [112]. Impaired endothelial
relaxation occurs in Marfan syndrome and has been shown
to be responsive to combined Losartan and Doxycycline ther-
apy [113] but to neither therapy alone. While coronary artery
disease is associated with endothelial dysfunction in the gen-
eral population, the vasomotor properties of the coronary
arteries in Marfan syndrome have not been studied.
Giusti documented that Marfan patients with the most
severe vascular changes, including aortic dissection, had sig-
nificantly higher homocysteine levels when compared to
patients with mild changes or normal controls [110].
Therapies shown to be both beneficial in aortic and coronary
artery disease, namely statins for hyperlipidemia [114,115] and
peroxisome proliferator-activated receptor (PPAR) gamma
agonists for diabetes [116] may be considered as adjuvant
therapies in at-risk patients. Both classes of drugs have been
shown to block TGF-beta activation.
In conclusion, genetic and environmental modifiers of
atherosclerotic coronary artery disease have been shown to
play a role in aortic pathologic changes in Marfan syndrome.
Attention toward the elimination of the risk factors may
improve long-term aortic health and reduce coronary artery
atherosclerosis.
7.2. Arterial tortuosity
Increasing attention to arterial tortuosity suggests that this is
quite common in Marfan syndrome, and increased tortuosity is
a sign of more aggressive systemic disease [117]. Tortuosity of
the carotid, subclavian, vertebral, and iliac arteries has been
described in Marfan syndrome since the late 1980s [117–121].
Once Loeys-Dietz syndrome was described as a separate
group of disorders commonly associated with arterial tortuos-
ity, there was discussion as to whether the tortuosity pre-
viously described was actually in cases of Loeys-Dietz
syndrome [122]. Studies then explored arterial tortuosity
using strict diagnostic criteria comparing Loeys-Dietz syn-
drome and Marfan syndrome [117,120]. In these two studies
of vertebral artery tortuosity, vertebral artery tortuosity was
common in both Loeys-Dietz syndrome (77-90%) and Marfan
syndrome (72-77%), although the degree of tortuosity was less
severe in Marfan syndrome. Using quantitative measures, the
degree of arterial tortuosity has been shown to be one of the
only independent predictors of adverse cardiovascular events
in Marfan syndrome apart from aortic dimension. This has
been demonstrated using both vertebral arteries and aortic
tortuosity indices [117,123,124].
7.3. Aneurysm and dissection of large- and medium-
sized arteries
Extra-aortic aneurysms and dissections are most commonly
noted as a consequence of aortic dissection, in which the
dissection extends to more distal vessels [119,121,125–127].
Less well characterized are aneurysms and dissection of the
peripheral vessels independent of aortic dissection. Isolated
peripheral aneurysms have been described in Marfan
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syndrome in the carotid, subclavian, axillary, internal mam-
mary, ulnar, iliac, and superficial femoral arteries [128–138]. A
few studies have attempted to characterize the true preva-
lence of dilation or aneurysms in those without prior interven-
tion. A study of 35 patients with Marfan syndrome without
prior aortic intervention were studied with thoracoabdominal
MRA [121]. This study demonstrated that 7 (20%) had aneur-
ysmal dilation of the peripheral vessels including the iliac
arteries, celiac artery, renal artery, and right subclavian artery.
Kono et al. also showed iliac artery aneurysm in 20% of
patients with Marfan syndrome who did not have dissection
extending to the abdominal aorta [120].
In individuals with prior intervention, aneurysms and dis-
section are more common [121,125,126]. In the study by
Mariucci, of the 29 patients who were status post-intervention
(although excluding patients with dissections), 14 (43%) had
dilation of an iliac, celiac, renal or subclavian artery [121]. In a
study of 100 patients with Marfan syndrome who had under-
gone arterial interventions for miscellaneous indications,
including aortic dissection, almost every patient had dilation
of at least 2 non-aortic arteries, and 20% needed additional
intervention in non-aortic arteries, most within 6 years of the
initial intervention [125]. In this study, 35% of patients who
suffered from type A or type B aortic dissection underwent
intervention of an extra-aortic arterial segment at some point.
A study by Yetman demonstrated that one-third of indivi-
duals in an adult cohort of patients with Marfan syndrome
(both with and without intervention/dissection) had periph-
eral vascular aneurysms, most detected incidentally during
CTA or MRA of the thoracoabdominal aorta [126]. Of the 47
peripheral aneurysms noted, 26 (55%) required intervention.
Gaertner et al. screened a smaller cohort of 21 patients with
Marfan syndrome (both with and without prior intervention)
for peripheral aneurysms, and similarly noted that 10 (48% of
all, 67% of the adults) had peripheral aneurysms, including in
the iliac, vertebral, brachiocephalic trunk, renal, subclavian,
femoral, popliteal, and axillary arteries [139]. Treatment of
peripheral aneurysms and dissection has been varied depend-
ing on location and extent [119,125,126]. Of note, vascular
tortuosity may make traditional techniques more challen-
ging [119].
7.3.1. Cerebral arteries
Rare cases of cerebral aneurysm in Marfan syndrome have
been documented since the first reported observation in
1971 [118,140–152]. These case reports suggested an
increased prevalence of cerebral aneurysms in Marfan syn-
drome compared to the general population. Followed were a
variety of conflicting publications, triggering debate on the
necessity of neurovascular screening. Depending on the type
of study and strictness of diagnostic criteria for Marfan syn-
drome, estimates of the prevalence of cerebral aneurysm have
ranged from 0% to >20% [143,153–156].
As better understanding has evolved regarding genetic
causes of aortopathy and arteriopathy, it is likely that some of
the early cases were actually separate genetic syndromes with
phenotypic overlap with Marfan syndrome. These include con-
ditions caused by mutations the TGF-ß pathway genes causing
Loeys-Dietz syndrome that are known to commonly have
neurovascular symptoms. Of note, as far as we know, none of
the case studies of cerebral aneurysm in Marfan syndrome
reported a known pathogenic FBN1 variant, although the origi-
nal case by Speciali did report ectopia lentis [140].
Cerebral artery dissection in Marfan syndrome appears to be
uncommon, but of patients presenting with cerebral dissection,
a diagnosis of Marfan syndrome should be considered. In a 44-
person cohort from China with intracranial vertebral–basilar
artery dissection, whole-exome sequencing demonstrated that
one patient had a FBN1 pathogenic variant and clinical features
consistent with Marfan syndrome. In a series by Kim et al., 2
dissections were noted in the 59 patients with Marfan syn-
drome who had neurovascular imaging [156]. In conclusion,
given the rarity of the condition in those with clear Marfan
syndrome, neurovascular screening is not currently recom-
mended, but there should be a low threshold for imaging if
symptoms suggest cerebrovascular involvement.
7.3.2. Spontaneous cervical artery dissection
Spontaneous dissection of the carotid and vertebral arteries, a
major cause of ischemic stroke in the young, is most often
idiopathic [157]. However, Marfan syndrome is often consid-
ered in the differential diagnosis. Both ultrastructural aberra-
tion of the arterial wall and arterial tortuosity have been noted
to be common in carotid artery dissection, invoking a possible
etiology as connective tissue disease [158,159]. However, cases
to date of confirmed Marfan syndrome and carotid or verteb-
ral artery dissection are almost always in the presence of prior
aortic dissection or surgery [160,161]. In two studies systemi-
cally evaluating 84 and 43 patients, respectively, with sponta-
neous cervical artery dissection, none had Marfan syndrome
[162,163]. In a large study of 1,934 consecutive patients with
cervical artery dissection specifically evaluating for inherited
connective tissue disease, only one had clinical Marfan syn-
drome; FBN1 testing was not performed [157]. This prevalence
is similar to that of Marfan syndrome in the general population
[164]. Given literature to date, there does not appear to be a
significant association between Marfan syndrome and sponta-
neous cervical artery dissection without a prior inciting event.
7.3.3. Visceral arteries
In Marfan syndrome, the visceral arteries are most commonly
involved after descending aortic dissection or graft repair,
when the visceral arteries are at risk of dissection and patch
aneurysm [127]. Rare cases of visceral artery aneurysms unre-
lated to dissection have also been reported in Marfan syn-
drome including in the gastric, celiac artery, splenic, and
hepatic arteries, almost all necessitating intervention
[120,121,125,137,165–167]. One study demonstrated that
Marfan syndrome was present in 3% of cases of visceral artery
aneurysms [165].
7.4. Expert opinion on patients’ reported symptoms
(Table 1)
Hypotension and syncope can both be indirectly related to
imbalances in blood pressure regulation which may be
impaired in patients with Marfan syndrome. Indeed, both
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orthostatic hypotension and autonomic dysfunction are more
commonly occurring in patients with Marfan syndrome.
Treatment with beta-blockers, or angiotensin receptor block-
ers, to slow aortic root growth, could be a reinforcing factor of
both. Ceasing beta-blockers did not normalize the abnormal
blood pressure response in one study [168].
7.5. Conclusion
In conclusion, extra-aortic vascular disease may occur in
Marfan syndrome. Both spontaneous coronary artery dissec-
tion and anomalous coronary artery origins have been
described, although it is unclear if the prevalence of these
conditions is higher than in the healthy population. Minimal
data exist about the atherosclerotic disease in Marfan syn-
drome, but clinical risk factors appear to be similar to the
rest of the population. The most common extra-aortic vascular
manifestations of Marfan syndrome are aneurysms of the
medium and large vessels and the visceral arteries. These
aneurysms are most common in patients who have had a
prior aortic dissection or prior cardiovascular surgery.
Intermittent serial screening by MR and CT angiography from
neck to pelvis in this subpopulation of patients with Marfan
syndrome should be considered. Literature to date does not
support a significantly increased risk of spontaneous artery
dissection or cerebral artery aneurysms in Marfan syndrome.
8. Lung features by Enid Neptune
The lung manifestations of Marfan syndrome are burdensome
and complex [169]. More importantly, they can lead to sub-
stantial disability and reduced quality of life. Scoliosis, pectus
deformities and respiratory muscle weakness contribute to
restrictive lung disease. Parenchymal lung disease, often
developmental in origin, leads to upper lobe blebs, pneu-
mothoraces and, especially in the setting of neonatal Marfan
syndrome, overt emphysema. Both chest wall deformities and
airway wall defects can manifest disorders such as asthma and
bronchiectasis. Finally, soft tissue laxity and a predilection for
upper airway obstruction confer the high prevalence of sleep-
disordered breathing. This spectrum of lung disorders is chal-
lenging for care providers who often have to evaluate dys-
pnea, chest pain and reduced exercise capacity in the context
of the known risks of highly morbid and fatal cardiac and
aortic disease. Unfortunately, no reliable contemporary (post-
Ghent 2010) assessment of lung disease prevalence is avail-
able given that screening for pulmonary impairment is incon-
sistent across centers and mostly symptom- or finding-
triggered [170]. However, even small, single-center retrospec-
tive studies confirm a high burden of respiratory disease in
Marfan syndrome [171].
8.1. Restrictive lung disease
Chest wall deformities such as scoliosis and pectus deformities
are common with Marfan Syndrome often resulting in restric-
tive lung disease [172]. With severe restriction, thoracic insuf-
ficiency syndrome (TIS) develops punctuated by impaired
ventilation and gas exchange [173]. In pediatric Marfan
syndrome, lung growth is further compromised by these dis-
orders directly impacting peak lung function attainment and
accelerating the onset of TIS. Scoliosis is the most common
spinal deformity in Marfan syndrome afflicting more than 60%
of patients [174]. Up to one-half of affected persons require
surgery for progression and/or associated respiratory compro-
mise [175]. Pectus deformities, namely pectus excavatum and
to a lesser degree pectus carinatum, are common congenital
disorders that are highly represented in Marfan syndrome
[176]. Most pectus deformities are mild and do not produce
marked alterations in lung function. However, more severe
pectus defects, especially when coupled to scoliosis, can
cause clinically consequential restrictive disease [177]. Less
invasive and more customizable surgical options (e.g., vertical
expandable prosthetic titanium ribs (VEPTR) magnetic rods, or
Nuss bars) for both scoliosis and pectus deformities are now
employed early in disease development leading to fewer
complications and lung function stabilization in selected
patients [178–182]. As yet, no long-term studies documenting
stability or improvement in lung function with these newer
interventions in the Marfan population are available.
8.2. Parenchymal lung disease
Long before the genetic cause of Marfan syndrome was dis-
covered, multiple case reports described spontaneous pneu-
mothorax as a feature [183]. Even now, spontaneous
pneumothorax, a minor systemic criterion in the Ghent algo-
rithm for Marfan syndrome, can be the initial clinical context
that ultimately leads to the Marfan syndrome diagnosis; none-
theless, the true prevalence among all Marfan syndrome
patients is unknown [170,184,185]. Small studies indicate a
much higher prevalence in Marfan syndrome compared with
the general population [171,186,187]. Upper lobe blebs, pul-
monary cysts, and overt emphysema, sometimes revealed as
incidental findings on imaging, all predispose to pneu-
mothorax. Because of this, the true prevalence of the airspace
findings in Marfan syndrome is unknown, but is likely much
higher than the incidence of pneumothorax. Recurrent and
bilateral pneumothoraces are also more common in Marfan
syndrome and despite surgical resection, blebs can reform
quickly. Accordingly, prophylactic surgical interventions are
not supported. Moderate or severe pneumothoraces, espe-
cially if tension physiology is demonstrated, merit mechanical
pleurodesis and local bleb resection. Chemical pleurodesis can
be hazardous if future aortic surgeries are anticipated. Other
approaches such as blood patches or bronchoscopic airway
valves (especially if a bronchopleural fistula is present) may
have special utility in the Marfan population but are under-
studied [188,189].
Mouse models of Marfan syndrome consistently show air-
space enlargement suggesting that airspace dysmorphology is
a primary and early feature of the syndrome. The likely
mechanism is a developmental disturbance in airspace forma-
tion triggered by the lack of fibrillin-1 during critical stages of
lung development. This pathogenetic scheme is supported by
the complex constellation of neonatal Marfan syndrome which
includes pulmonary emphysema as well as severe cardiovas-
cular impairments [190,191]. Further, a histologic survey in
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early-onset acquired emphysema showed reduced levels of
fibrillin-1 expression in the airspace compartment [192].
Fortunately, therapeutic considerations are emerging. While
Losartan shows efficacy for emphysema reversal in mouse
models of Marfan syndrome, no clinical trials have thus far
included pulmonary outcomes [193].
8.3. Airway disorders
Airways obstruction on pulmonary function testing and/or
recurrent wheezing have been reported in Marfan syndrome
[194]. The anatomic basis for this manifestation is unclear and
may reflect airway smooth muscle dysfunction as a conse-
quence of altered matrix composition or direct airway com-
pression from chest wall deformities. Additionally, primary
alterations in the immune milieu might contribute similarly
to the allergic airways disease observed in Loeys-Dietz
Syndrome [195]. A few case reports detail bronchiectasis in
Marfan Syndrome which could also reflect primary large air-
way wall pathology [196,197]. For all of these disorders, the
use of aerosolized β-adrenergic agonists is discouraged given
potential cardiovascular side effects as well as antagonistic
interactions with β-blockers. Inhaled anticholinergic and
inhaled corticosteroids are the preferred treatments.
8.4. Expert opinion on patients’ reported symptoms
(Table 1)
Table 1 does not include very common symptoms that Marfan
patients, and their physicians, often attribute to cardiac dis-
ease or deconditioning such as dyspnea with exertion,
reduced exercise capacity or chest pain. These symptoms
may reflect lung disorders that are underdiagnosed in persons
with Marfan syndrome such as asthma, bullous lung disease,
or restrictive lung disease. Early involvement of lung specia-
lists to evaluate these symptoms would serve the interests of
the Marfan population.
8.5. Conclusions
In conclusion, a variety of lung features occur with Marfan
syndrome that can lead to reduced quality of life and progres-
sive disability. Awareness of these complications with early
diagnosis and appropriate interventions is crucial. Close mon-
itoring of lung function, standardized to sitting rather than
standing height, and exercise capacity by pulmonary specia-
lists should be incorporated into a coherent multidisciplinary
Marfan care plan [198].
9. Sleep physiology features by Laura Muiño-
Mosquera
9.1. Obstructive sleep apnea (OSA)
The first reference to sleep apnea in Marfan syndrome dates
from almost 30 years ago. In 1991 Cistulli and Sullivan first
described six patients with Marfan syndrome (2 females, age
range 15-43yrs), all of whom presented obstructive sleep
apnea syndrome [199]. Further research confirmed that the
prevalence of sleep apnea in patients with Marfan was rela-
tively high, ranging from 31% to 64% [200–202] depending on
the studied cohort and the method used to test sleep apnea.
In fact, two studies found that in comparison to sex- and age-
matched controls, the prevalence of sleep apnea in Marfan
patients was significantly higher [200,201].
9.2. Central sleep apnea (CSA)
Three different types of sleep apnea can be distinguished:
central, obstructive and mixed. Most commonly, patients
with Marfan syndrome present obstructive episodes, but
one study also found high prevalence of central sleep
apnea [202]. The obstructive episodes can be explained by
the characteristic facial features (retrognathia, malar hypo-
plasia, dolichocephaly) in combination with higher airway
collapsibility [203,204]. Furthermore, patients with a high
body mass index seem to have higher prevalence of obstruc-
tive sleep apnea [201,202,205]. Why patients with Marfan
syndrome present central sleep apnea is not clear, but it
may be related to impaired left ventricular function in
some patients, and autonomic system dysregulation in
others [202,205]. Detection of sleep apnea through a ques-
tionnaire is cumbersome because there is a poor correlation
between the score and the presence of sleep apnea. In our
experience, the STOP-bang questionnaire seems to have the
best positive predictive value [205].
9.3. Clinical consequences of sleep apnea
Individuals with sleep apnea that is unrelated to Marfan
syndrome appear to have a higher cardiovascular risk, show-
ing a higher prevalence of hypertension, stroke, and arrhyth-
mia [206–210]. Higher systolic blood pressure and higher
prevalence of ventricular arrhythmia were mildly associated
with sleep apnea in Marfan syndrome in one study [205] and
with higher incidence of atrial fibrillation in another [202]. In
the general population, the relationship between sleep
apnea and aortic diameters is less-well studied and the
findings are inconsistent [211–214]. Similarly, in Marfan syn-
drome patients the relation between sleep apnea and aortic
root growth is debated: while some studies find an associa-
tion [201,215], others fail to do so [202,205]. The influence of
sleep apnea in other organ systems and in the quality of life
has not been studied in Marfan syndrome but could be very
relevant. In our own experience, treatment of sleep apnea in
patients with Marfan syndrome is successful and improves
fatigue and quality of life.
Treatment strategy is the same as in the general population
and consists of weight reduction (in those patients with over-
weight) and nasal continuous positive airway pressure (CPAP).
9.4. Expert opinion on patients’ reported symptoms
(Table 1)
Interestingly, patients do not report symptoms of sleep-disor-
dered breathing (Table 1). Patients will typically not report
sleep apnea as a symptom but will often complain of fatigue
which is an inherent consequence. Also, interrogating the
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patient’s bed partner may reveal relevant information regard-
ing snoring and arousals.
9.5. Conclusion
In conclusion, sleep apnea is highly prevalent in patients with
Marfan syndrome. Although the typical Marfan physiognomy
and higher airway collapsibility are, in part, responsible for this
higher prevalence, overweight, especially in older ages, is an
important and modifiable risk factor to be taken into consid-
eration. Although sleep apnea does not clearly increase cardi-
ovascular risk in patients with Marfan syndrome, further
research in this field might be necessary to elucidate whether
patients with Marfan syndrome might benefit from an earlier
and more aggressive treatment.
10. Abdominal features by reed Pyeritz
No abdominal features are currently included in the nosology
of Marfan syndrome, although several features with variable
relevance have been reported.
10.1. Liver and kidneys cysts
A manifestation that clearly is of increased prevalence is cyst
formation in the liver and kidneys [216]. These first were
recognized incidentally on imaging of the abdomen per-
formed for cardiovascular indications. Their prevalence is
clearly greater than in age-matched controls (59% vs. 30%
for renal and 35% vs. 17% for hepatic cysts). Some cysts can
become quite large, but other than a mass effect on surround-
ing tissue, the cysts are benign and harmless. Their age of first
appearance and growth in both number and size over time
have not been examined. Some confusion with adult polycys-
tic kidney disease exists in the older literature.
10.2. Biliary tract features
Cholelithiasis may be more common in Marfan syndrome (in
the only study of unselected, asymptomatic patients, 18% vs.
2% of controls) [216]. Biliary duct ectasia, likely contributing to
bile stasis has been reported [217].
10.3. Diaphragmatic hernia
In individual patients, especially those with severe, neonatal
Marfan syndrome, a dozen or so reports of diaphragmatic
hernias of various types occur. In fact, the presence of a
diaphragmatic hernia in children is one predictor of reduced
life-expectancy [218]. Congenital hernias may not be detected
until later in life [219]. A reporting bias in older patients
undoubtedly exists, certainly when an abdominal complica-
tion has occurred in association with a hernia. Variants in
FBN1, as well as other genes, contribute to familial congenital
diaphragmatic hernia independent of Marfan syndrome [220].
10.4. Other abdominal features
The same reporting bias pertains to intestinal issues, such an
intussusception, volvulus, diverticulosis, and rupture. In one
retrospective examination of adults admitted for diverticulosis,
a slight association with Marfan syndrome (odds ratio = 2.4)
was found [221].
10.5. Adiposity
Most people with Marfan syndrome accrue adiposity as they
age [104]. In Marfan syndrome, this is most pronounced in the
abdomen, and the appearance is accentuated by the persis-
tent slimness of the extremities. Increased visceral fat predis-
poses to insulin resistance and type 2 diabetes mellitus, and
may predispose to aortic complications [104]. The adiposity is
composed of white fat, in distinction to brown fat that is
subcutaneous. Fibrillin-1 plays both a structural and hormonal
role in the differentiation of adipocytes, so pathogenic variants
in FBN1 may likely contribute to the deposition of fat in the
abdomen. Since the BMP pathway is involved in adipocyte
differentiation, it would be interesting to determine if the TGF-
β pathway is involved and if medication, such as angiotensin
receptor blockers, might decrease visceral fat accumulation.
This hypothesis might be pursued with additional data
[222–224].
10.6. Expert opinion on patients’ reported symptoms
(Table 1)
The patients’ complaints of abdominal symptoms do not
appear to relate to any of the Marfan-specific features dis-
cussed in this chapter or to any other potential features of
Marfan syndrome that I am aware of.
10.7. Conclusion
All of these potential abdominal issues, as well as cardiovas-
cular ones, should be considered in any person with Marfan
syndrome presenting with abdominal features, particularly in
older patients.
11. Urogenital features by Thy Thy Vanem
11.1. Kidney cysts
An increased prevalence of small renal cysts was already men-
tioned above. Although small renal cysts usually are benign, it
has been assumed that cystic kidney disease is associated with
aneurysm progression in Marfan syndrome and that such cysts
should be considered as markers for aortic aneurysm develop-
ment [225,226]. It is not known if the formation of renal cysts
in Marfan syndrome is influenced by TGFβ1 or if it is due to a
structural failing of microfibrils [216]. A case report of Marfan
syndrome mouse with renal cystic disease, extreme aortic
dilatation and increased vascular inflammation suggests that
cystic renal disease may be causally involved in the pathogen-
esis of aortic aneurysm formation by promoting aortic inflam-
mation [226].
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Linking renal cysts with Marfan syndrome is also suggested
from the opposite way: patients with autosomal dominant
polycystic kidney disease (ADPKD) clearly show an increased
prevalence of aortic root aneurysms [227]. In patients with
ADPKD, some systemic features reminiscent of Marfan syn-
drome have been reported in ADPKD patients [228–230]. The
process of aortic aneurysm formation in ADPKD is incomple-
tely understood. The proteins encoded by the genes involved
in ADPKD (PKD1 and PKD2) encode components of the poly-
cystin complex which is regarded as an important mechan-
osensor in the kidney – a role in the aortic wall is not
established [231]. Dysregulated TGF-β signaling has also
been suggested to play a role in the development of aortic
aneurysms based on studies in mouse models. Double hetero-
zygous mice with targeted mutations in Pkd1 and Fbn1 dis-
played a more severe aortic phenotype, which is according to
further experiments related to further upregulation of TGF-ß
signaling caused by Pkd1 haploinsufficiency.
11.2. Other renal features
Several other renal features have been described in case
reports in Marfan syndrome patients, such as nephrotic syn-
drome due to focal segmental glomerulosclerosis, medullary
sponge kidney, recurrent nephrolithiasis, glomerular basement
alterations, renal vascular anomaly and renovascular hyperten-
sion [232–239]. The prevalence of kidney disease in Marfan
syndrome is not known and there is no established evidence
of the association between kidney diseases and Marfan syn-
drome. However, one paper suggests that microfibrillar disar-
rangement can be the cause of glomerular basement
membrane alterations in Marfan syndrome [232].
11.3. Premature labor
Cardiovascular complications are known risks in pregnant
Marfan syndrome women, as well as increased risk of obstetric
and fetal/neonatal complications compared to healthy con-
trols [240]. There are several studies on pregnancy outcome
in Marfan syndrome women, but few studies describing spe-
cifically premature labor in Marfan syndrome women,
although premature labor is one of the most common reasons
for hospitalization of pregnant women in the general popula-
tion. One paper reports a case of a Marfan syndrome woman
who experienced premature labor in five out of six pregnan-
cies, but with no evidence of cervical incompetence [241].
Several studies have reported similar rates of preterm births in
Marfan syndromegroups compared to the general population [242–
245]. However, one retrospective study from 2006 found an
increased percentage of preterm deliveries due to the preterm pre-
mature rupture ofmembranes and cervical incompetence inMarfan
syndrome women [246]. In a study from 2014, 29 pregnancies in 21
Marfan syndrome women were compared to 116 controls [240].
Only pregnancies beyond 24 weeks of gestational age and only
singleton pregnancies were included in this study. Two babies (7%)
in theMarfan syndromegroupweredeliveredpreterm iatrogenically
due tomaternal reasons, none due to spontaneous premature labor.
11.4. Urinary incontinence
It has been assumed that connective tissue abnormality can
contribute to urinary incontinence [247,248], and a high preva-
lence of urinary incontinence has been reported in women with
Marfan syndrome [247–249]. However, urinary incontinence is
common in women in general and the estimated prevalence
varies depending on several factors, among them the popula-
tion studied. In adult women in the general population, an
estimated prevalence of nearly 50% has been reported, but
few patients seek help for the condition [250–252]. Lower pre-
valence of 10-17% has been reported in non-pregnant women
age 20 years and above [253,254]. In a study by Jabs, a signifi-
cantly higher prevalence was found in female Marfan syndrome
patients compared to the general population [255]. Eighty-eight
patients reported a history of urinary incontinence and 72% had
experienced episodes of stress incontinence. Of these, 52%
considered the problems as significant. In this Marfan syndrome
population, stress incontinence was not associated with parity.
In a study by Chan et al. patients with Marfan syndrome had
significantly higher incidence of urinary symptoms, stress incon-
tinence and urge incontinence compared to controls, despite
lower parity in the Marfan group [247]. None of the studies have
found correlations between joint hypermobility and stress
incontinence.
11.5. Expert opinion on patients’ reported symptoms
(Table 1)
Patients reported bladder problems, urinary tract infection and
premature labor as major complaints, and urinary inconti-
nence, maldescensus testis, ovarian cysts, and kidney stones
as minor/rare complaints (Table 1). As far as not addressed
above, we will try to comment according to what is known
from the literature:
● Urinary disorders are not frequent in Marfan syndrome,
and apart from urinary incontinence, no studies describe
other chronic urinary tract symptoms or increased urin-
ary tract infection in patients with Marfan syndrome. One
paper describes four patients with urinary problems sec-
ondary to vascular or neurological complications related
to Marfan syndrome [256].
● We have found one paper describing a case of seminoma
in Marfan syndrome [257]. Apart from this, we have not
found studies describing associations between specific
urogenital features and Marfan syndrome, such as mal-
descensus testis, which is the most common congenital
anomaly in the genitourinary tract [258].
● Marfan patients have reported ovarian cysts and kidney
stones as minor complaints. However, we have not
found any studies to confirm any relations between
these findings and Marfan syndrome. Two papers
describe cases where a pelvic mass was initially misdiag-
nosed as an ovarian cyst, but where further investiga-
tions revealed an anterior sacral meningocele, which is a
severe form of dural ectasia, a known feature of Marfan
syndrome [259,260].
898 Y. VON KODOLITSCH ET AL.
11.6. Conclusion
There is no evidence of associations between kidney diseases
and Marfan syndrome. One study indicates an increased per-
centage of preterm deliveries in women with Marfan syn-
drome. There are few studies on premature labor in women
with Marfan syndrome. Urinary disorders are not common in
Marfan syndrome, but urinary incontinence has been sug-
gested to be added to the list of clinical features in Marfan
syndrome women.
12. Musculoskeletal features by Nina Riise
12.1. Myopathy
Skeletal muscle abnormalities including variation in fiber size,
overall reduced fiber size, fatty infiltration, excessive matrix
between fibers and a reduced number of proliferating satellite
cells have been described in ‘large subsets’ [261] or ‘many
individuals’ [262] with Marfan syndrome [263] but the clinical
evidence is sparse. However, decreasing muscle mass over
time also has been described [264].
TGF-beta1 has a known role in signaling in skeletal muscle.
Increased TGF-beta1 activity leads to failed muscle regenera-
tion [262] and fibrosis [265]. It may lead to the formation of
scar tissues, weakened muscle function, pain and increased
risk of reinjury [266].
Marfan syndrome myopathy may cause muscle fatigue and
weakness [267], myalgia, cramps [268], inability to increase
muscle mass despite physical exercise, hypotonia [261,262],
and reduced muscle mass [264,268]. It may be associated with
reduced bone mineral density [264] and respiratory failure [269].
There is no current therapy. Losartan and retinoic acid have
shown a beneficial effect on muscles in experimental models
[262,270].
12.2. Reduced bone mineral density
Several studies reported reduced average bone mineral den-
sity in Marfan syndrome [264,271–277]. However, other stu-
dies do not corroborate a reduced bone mineral density [278–
280]. The prevalence of osteoporosis in Marfan syndrome is
unknown. The studies that are available have several metho-
dological weaknesses, and different diagnostic criteria are
used. Some studies point out that bone mineral density
decreases over time [264,277]. Defective fibrillin-1 leads to
improper over activation of latent TGF-beta, enhanced osteo-
blast maturation and osteoblast-supported osteoclast activity,
which could account for reduced bone mineral density
[281–283].
In conclusion, it is unclear whether patients with Marfan
syndrome have reduced bone mineral density, and if so,
whether this translates into an increased risk for bone frac-
tures [271,275]. However, clinicians should be aware of this
possibility, and screening with dual-energy X-ray absorptiome-
try (DEXA) should be considered in individuals with clinical risk
factors or symptoms. There is no evidence on the prevention
or treatment of osteopenia or osteoporosis in Marfan syn-
drome. General guidelines should be followed. A few studies
have shown conflicting results on the effect of losartan on
bone mineral density [277,284,285]. There are no studies on
bone mineral density in groups of older people with Marfan
syndrome; hence, the long-term prognosis is unknown.
12.3. Craniofacial features
Information about facial dysmorphism in Marfan syndrome
may be useful for early recognition of the disease [286,287].
A recent study using 3-dimensional skeletal imaging reported
greater facial divergence and a lower facial height index as a
uniform feature in adults with Marfan syndrome [286].
Another study [288] described a retrognathic maxilla in 81%
and retrognathic mandible in 89%. The mandibular ramus is
short [286,288]. Large frontal sinuses [288] and high nasal
airway restriction associated with maxillary restriction have
been described [289].
The facial features listed in the revised Ghent criteria [170]
comprise dolichocephaly, malar hypoplasia, enophthalmus,
retrognathia, and downslanting palpebral fissures. These
have been found to yield a diagnostic sensitivity of 28–54%
and a specificity of 91–99% for Marfan syndrome [287,290].
The craniofacial features may increase the risk of obstructive
sleep apnea [289] and cause dental crowding and overjet
[288] necessitating orthodontic treatment in some cases [288].
The cause of the craniofacial abnormalities in Marfan syn-
drome is not clear. Fibrillin insufficiency in the periosteum and
inserting muscles, improper response to deficient tension in
periosteum and sutures leading to ‘long face’ growth or oral
breathing are suggested explanations [291].
12.4. Expert opinion on patients’ reported symptoms
(Table 1)
Deviated nasal septum and sinusitis have been described as
common, and allegedly large tonsils and adenoids can con-
tribute to otitis in Marfan syndrome [292]. However, there are
no data to confirm this. Vertebral body hemangioma and
ingrown toenails are not described as features of Marfan
syndrome. Manifest osteoporosis may be more frequent than
in the general populations, as some studies describe an
increased prevalence of decreased bone mineral density.
Marked abnormalities in the pelvic values compared with
those found in the unaffected population, with increased
retroversion of the pelvis, in particular, were found in one
study [293].
12.5. Conclusion
People with Marfan syndrome may have myopathy as part of
the syndrome, but the prevalence, severity, and mechanisms
are poorly described. Decreased bone mineral density has
been described in people with Marfan syndrome. However,
the evidence is conflicting, and the clinical relevance is
uncertain.
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13. Dermatological features by Leema Robert
Skin striae are one of the systemic features that is scored in
the revised nosology for Marfan syndrome. One of the first
studies to document skin and joint hypermobility in patients
with Marfan syndrome was undertaken by Grahame and
Pyeritz in 1995 [294], clearly documenting striae, atrophic
scars, and skin hyperextensibility, all increasing with age.
Striae atrophicae were the most common finding and were
documented in two-thirds of patients in this study. Papyrous
scars were present but not as large as those seen in Ehlers-
Danlos syndromes. A clear and significant association of skin
features in and presence of hyperextensible joints was also
demonstrated in patients with Marfan syndrome. It deserves
to be documented that patients ascertained for this study
were from a single clinic in Maryland, USA. Their diagnosis
was established on the presence of unequivocal clinical
features of Marfan syndrome.
Another key paper that documents skin features is the study
undertaken by Ledoux et al. [295], which is a systematic review
of skin and cutaneous features in 61 consecutive patients with
age, sex and height matched controls. Sixty-six percent of indi-
viduals with Marfan syndrome had striae when compared to
16% of controls. Similar to the Grahame and Pyeritz paper, large
hypertrophic or atrophic scars were also documented in higher
frequency in Marfan syndrome vs controls (46% vs 21%).
Hyperpigmented or hypopigmented scars were also noted.
Other features documented include hernia (5 in Marfan syn-
drome vs 4 in controls), fibroma (1 vs 1), and purpura (1 vs 1).
In contrast to the Grahame and Pyeritz paper, the 49 Marfan
syndrome patients in this cohort had undergone genetic testing
with a proven pathogenic variant in FBN1 in 34 patients and a
TGFBR2 variant in one patient. The incidence of striae however is
similar to the previous publication and two-thirds of patients
were noted to have this dermal manifestation. The clear distinc-
tion however is the presence of striae in uncommon areas of the
body in Marfan syndrome patients. Adult patients with Marfan
syndrome demonstrated numerous striae on shoulders, breast,
flanks, hips, and buttocks. The authors therefore conclude that
striae could be a used a good diagnostic criterion for Marfan
syndrome, particularly if they located in atypical sites. The
authors therefore conclude that striae could be used as a
good diagnostic criterion for Marfan syndrome, particularly if
they located in atypical sites.
Several single case reports of various skins and cutaneous
involvement have been published. It is debatable whether
these are just coincidental findings as the larger studies
described do not validate these findings. These case reports
and case series on skin and cutaneous features reported in
Marfan syndrome are briefly outlined below.
● Alopecia universalis: Ziv et al. describes non-scarring
alopecia of the whole body (alopecia universalis) in a
case with clinical features of Marfan syndrome [296].
● White forelock: Herman et al. describe an unusual asso-
ciation of white forelock in a case with clinical features of
Marfan syndrome [297].
● Vermiculate atrophoderma: Harper et al. describe a 14-
year-old boy with clear clinical features of Marfan syn-
drome with vermiculate atrophoderma [298].
● Lichen planus: Nallegowda et al. report on pterygium of
both upper and lower limb nails in a patient with clear
clinical features of Marfan syndrome [299]. This was con-
cluded as Lichen planus where variable involvement of
nails are well documented.
● Lipodystrophy: A case with de novo pathogenic variant
in exon 64 of the FBN1 gene (c.8155_8156del2) was
described with severe generalized lipodystrophy and
progeroid features. Other lipodystrophy conditions
were considered and excluded. Graul- Neumann et al.
considered dual pathology in their patient and possibility
of a mutation-specific phenotype was raised [300].
● Atrophic skin patches: Bergman et al. report atrophic skin
patches with abnormal elastic fibers in a 50 years old
patient with a MASS phenotype. Genetic testing identi-
fied a missense mutation in exon 27 of the FBN1 gene
(c.3422C>T; p.Pro1141Leu) [295].
13.1. Expert opinion on patients’ reported symptoms
(Table 1)
Psoriasis: This is very likely a coexisting condition rather than a
skin manifestation of Marfan syndrome. As outlined by the
British skin foundation, psoriasis is a common immune-
mediated skin condition that affects 1 in 50 people. This
often manifests as dry scaly skin. Common-affected areas
include scalp, elbows knees, hands and feet, and skin folds.
Plantar soft tissue tumors: These are not described in asso-
ciation with Marfan syndrome. Piezogenic papules are small
soft tissue herniations seen in weight-bearing areas of the
foot. These are described in mild connective tissue disorders.
Careful evaluation of soft tissue tumors by clinicians would be
recommended but a specific association with Marfan syn-
drome currently remains undetermined.
Dry Scaly Skin: The most common causes of dry, scaly skin
are eczema and psoriasis. Although eczema and immune dys-
regulation are noted in other connective tissue disorders such
as Loeys-Dietz syndrome, the association in Marfan syndrome
remains undetermined.
13.2. Conclusion
The key skin features noted in Marfan syndrome are striae and
atrophic scars. As outlined above systematic documentation of
skin and cutaneous manifestations by Grahame and Pyeritz
[294] and Ledoux et al. [295] provide data on the prevalence
of cutaneous manifestations in contrast to single case reports.
Although association with other dermal features has been
noted, further systematic reviews are needed to study the pre-
valence of these features in Marfan syndrome versus controls.
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14. Dental features by alexander Rahman and
Ingmar Staufenbiel
Only few studies investigated dental aspects of Marfan syndrome.
Oral manifestations can affect the dental hard and soft tissues
and the periodontium. Marfan syndrome can lead to orthodontic
changes as well as degeneration of the dental pulp. It may also
increase the prevalence of craniomandibular dysfunction.
14.1. Caries
In 2002 De Coster et al. investigated structural defects of
enamel and dentine [301]. They found that hypoplastic
enamel areas were more often found in patients with Marfan
syndrome. Therefore, they concluded that patients with
Marfan syndrome may have a higher risk of caries. In contrast,
Rahman et al. investigated the prevalence of dental caries in
31 children with Marfan syndrome. No increased prevalence of
caries in Marfan syndrome patients was documented com-
pared to healthy children [302].
Staufenbiel et al. examined the periodontal health of 51
patients with Marfan syndrome as compared to 31 control
subjects. We used a complete periodontal status including
probing pocket depth, clinical attachment level, and bleeding
on probing. The mean values of the clinical attachment level
were almost identical in both groups (2.62 ± 0.56 mm in the
Marfan syndrome group compared to 2.70 ± 0.61 mm in the
control group), indicating that patients with Marfan syndrome
did not have a higher risk for periodontal disease [303].
14.2. Orthodontic manifestations
From an orthodontic point of view, a narrow upper jaw with a
high palate, a skeletal class II with retrognathy of the lower
jaw and crowding of teeth is frequently observed in patients
with Marfan syndrome [291].
Additionally, Bauss et al. described a significantly higher
prevalence of pulp stones and pulp calcifications in patients
with Marfan syndrome [304]. These alterations are not consid-
ered to be a disease but they may cause higher complication
rates during root canal treatments.
Based on clinical and radiological findings, a significantly
higher prevalence of craniomandibular dysfunction was
detected in patients with Marfan syndrome [305].
14.3. Expert opinion on patients’ reported symptoms
(Table 1)
The major complaints described by the patients could be under-
stood as crowded teeth described in several studies. As a result of
the crowded teeth the oral hygiene procedures are compromised
and could explain the increased gum bleeding. The tendency to
more inflammations signs as well as structural defects of enamel
is symptoms which can be found in the scientific literature.
14.4. Conclusion
Especially because of the elevated signs of inflammation we
recommend more frequent dental maintenance in patients
with Marfan syndrome. This should include professional oral
hygiene appointments to reduce the bacterial load in the oral
cavity. As endocarditis is frequently caused by oral bacteria,
oral health care can be regarded as endocarditis prophylaxis.
15. Headache as neurological symptom by Anji
Yetman
Headaches are common in Marfan syndrome and may occur
secondary to migraines, intracranial hypotension, and carotid
artery dissections [306]. The first two are discussed below, the
last one is discussed as vascular manifestation.
15.1. Migraine
Numerous case-control studies have documented a higher
incidence of migraines both with and without aura in patients
with Marfan syndrome [306,307]. In the largest series to date,
40% of patients with Marfan syndrome compared with 28% of
age- and gender-matched controls met diagnostic criteria for
migraine headache [306]. Treatment for migraines in patients
with Marfan syndrome may differ from the general population.
Therapies commonly used for the reduction of aortic aneur-
ysmal disease, namely angiotensin receptor blockers, ACE
inhibitors, and propranolol have all been used successfully
for the reduction of migraine burden [306,308].
15.2. Spontaneous cerebrospinal fluid (CSF) leakage
Much less common than migraine headaches, headaches sec-
ondary to intracranial hypotension may occur in Marfan syn-
drome [306,309–315]. Intracranial hypotension occurs as a
result of low pressures of CSF within the subarachnoid space
secondary to spontaneous leaks of CSF most commonly from
the lumbar or sacral dura at the site of dural ectasia [306].
While dural ectasia has been documented in 40% of children
and 63-95% of adults with Marfan syndrome [314], only a
small fraction of these patients are diagnosed with intracranial
hypotension. The phenomenon has been seen across the age
spectrum including children as young as 5 years [306,316].
In contrast to migraines, patients with intracranial hypo-
tension typically experience headaches that worsen with
standing and improve with recumbency [306]. Other symp-
toms are often nonspecific and include nausea, dizziness,
neck stiffness, decreased hearing, or blurred vision [315].
Headaches may be non-positional and may be associated
with exertion. In some cases, they may be paradoxic, worsen-
ing with lying down. Minor trauma, or an intense Valsalva
maneuver as may occur with coughing, bowel movements or
labor [310,313] have been identified as causative factors in
the dural leaks responsible for this phenomenon. Because of
the marked clinical variability that may be present with intra-
cranial hypotension, diagnostic criteria for spontaneous intra-
cranial hypotension have been established and include at
least one of the following: A. the demonstration of extrathe-
cal CSF on spinal imaging which may include CT myelogra-
phy, MR imaging or MR myelography, or B. cranial MR
imaging findings of spontaneous intracranial hypotension
(subdural fluid collections, enhancement of the
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pachymeninges, sagging of the brain) with at least one of the
following: 1. Low opening CSF pressure; 2. Spinal meningeal
diverticulum; 3. Improvement of symptoms after epidural
blood patch, or in the absence of A or B, C. Presence of 1, 2
and 3 above [317]. Complications may stem from failure to
recognize the etiology of the headache thereby not providing
adequate therapy. Patients with intracranial hypotension may
present with a picture of dementia, quadriplegia or
coma [317].
Therapy for intracranial hypotension may include conserva-
tive measures such as fluids, bed rest and caffeine [316] how-
ever the most commonly used initial treatment is epidural
blood patching [317]. The improvement in symptoms after
an epidural blood patch may be temporary and the procedure
can be repeated.
15.3. Expert opinion on patients’ reported symptoms
(Table 1)
Patients with extreme height have a higher incidence of
orthostatic hypotension manifesting as postural dizziness or
syncope. The source of the hypotension in such individuals is
said to be cerebral hypotension [318]. Given almost universal
tall stature in patients with Marfan syndrome, it is not surpris-
ing that postural dizziness is a frequent occurrence. Mulder et
al. found both postural dizziness and fatigue to be more
frequent in patients with Marfan syndrome than in the general
population and noted that the two symptoms were strongly
correlated and occurred independent of the use of beta-
blocker therapy [168]. Use of physical counter pressure man-
oeuvers such as knee-bending, or leg crossing may be helpful.
15.4. Conclusion
Headaches in Marfan syndrome are frequent and can be dis-
abling. Accurate diagnosis of the underlying etiology is impor-
tant to direct effective therapies. Cerebral and spinal imaging
may provide important clues as to the underlying etiology.
Intracranial hypotension should be considered in patients with
refractory, positional or complicated headaches that do not
respond to conservative management.
16. Psychological features by Svend Rand-
Hendriksen
The literature about psychosocial features in individuals with
Marfan syndrome is sparse. In most studies published, the
clinical information given does not secure the Marfan syn-
drome diagnosis in accordance with recent diagnostic criteria
(Ghent-1; 1996 or Ghent-2; 2010) [170,319]; DNA investigations
are only performed in a few more recent studies.
Consequently, the described cases and families may have
one of the related heritable thoracic aortic diseases that
have been discovered more recently. Whether psychosocial
features are inherently part of Marfan syndrome, a conse-
quence of Marfan syndrome, or incidentally co-occur with
Marfan syndrome is largely unknown.
16.1. Cognitive dysfunction
A higher prevalence of cognitive dysfunction in children and
young adults with Marfan syndrome has been suggested in
two papers, based on clinical questioning about the presence
of learning disabilities, attention deficit hyperactivity disorder
(ADHD), neuro-maturational immaturity and/or performance
IQ score was different from their verbal score by more than
20 points: Hofman (1988) reports 50% [320], while Handisides
(2019) reports 27% [321]. No prevalence studies have been
published. Two studies have published data from neuropsy-
chological testing, both with small samples: Lannoo (1996)
found very small differences in neuropsychological function-
ing in comparison to a group of healthy volunteers among 13
patients aged 14 to 56 years [322], whereas our own group
(2007) found cognitive abilities within normal range among 16
young adults [323].
Inborn cognitive dysfunction, reported as prevalent in the
primary description of Loeys-Dietz syndrome (2005) [122],
does not seem prevalent among persons with Marfan syn-
drome. However, for the single individual, early diagnostics
and relevant stimulation and support are of high importance.
In conclusion, the prevalence of cognitive dysfunction
among people with Marfan syndrome is probably comparable
to the general population. To find the true prevalence of
cognitive dysfunction in Marfan syndrome, larger studies in
persons with clinically and genetically confirmed Marfan syn-
drome must be done.
16.2. Schizophrenia
Case reports reported on individuals and their families with
coexistence of Marfan syndrome and schizophrenia [324–334].
Some early papers suggested that symptoms of schizophrenia
are a part of Marfan syndrome, and later papers have sug-
gested that the cause of schizophrenia should be linked to the
FBN1 gene. However, a linkage study failed to demonstrate a
common genetic factor [328]. In conclusion, for most of the
papers, diagnostic information is sparse and the diagnosis of
Marfan syndrome appears questionable.
16.3. Depression
Eight papers described the coexistence of Marfan syndrome
and depression [329,335–341]. However, again, most are case
reports with questionable clinical data regarding the diagnosis
of Marfan syndrome. Of the five papers presenting groups of
patients, one is based on self-reported diagnosis of Marfan
syndrome [337]; the other four studies based on the diagnosis
of Marfan syndrome on Ghent-1 or Ghent-2. DNA investiga-
tions are not presented. The studies use different methods to
assess depression. The reported prevalence of depression is
diverging from ‘no difference between Marfan syndrome and
control [339], “within normal range” [340] to “depression ever
in 24,8%” [341] and “depressive symptoms” in 44%’ [337].
In conclusion, the prevalence of depression among people
with Marfan syndrome is probably similar as in the general
population. To assess the true prevalence of psychiatric pro-
blems including schizophrenia and depression in Marfan
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syndrome, larger studies in patients with confirmed Marfan
syndrome should be performed.
16.4. Fatigue
Patients with Marfan syndrome have reported fatigue as a
severe problem. Six reports focused on fatigue
[168,268,323,340,342–345]. In all reports, the diagnosis of
Marfan syndrome was based on Ghent-1, except for one
paper in which the revised Ghent nosology was used [345].
None of the papers report DNA investigations. All reports
document a higher level of fatigue in Marfan syndrome than
in the general population. Two papers even report ‘severe
fatigue’ in around 40-50% of the patients [342,345].
In conclusion, fatigue should be considered as an impor-
tant feature among patients with Marfan syndrome which
needs to be acknowledged in the life-long follow-up.
16.5. Pain
In our personal experience, some patients with Marfan syn-
drome experience pain as a severe and chronic problem. Of
these, some individuals had undergone cardiac surgery, some
were permanent opiate users and others were addictive users
also of other pain medications. In the literature, the prevalence
of pain in Marfan syndrome ranges from 47% to 91%, and
mean values of pain are reported higher than in the general
population.
Eighteen papers, published before 15 May 2015, presenting
data about pain in Marfan syndrome, are included in a sys-
tematic review by Velvin et al. [346]. Of these, only the study
by Nelson et al. had its primary focus on pain [347]. Across the
various studies, the methods of patient sampling, Marfan syn-
drome diagnostics, and tools for measuring pain were diver-
ging, and the prevalence, extent, and type of pain varied
accordingly. However, chronic pain is reported to be more
prevalent in Marfan syndrome than in the general population.
Back pain, neck pain, shoulder pain, chest pain, knee pain, and
headache/migraine (see above) are the most commonly
observed types.
After May 2015, another relevant paper was published:
Speed et al. reported on a questionnaire-based study in 245
people with self-reported Marfan syndrome [348]. Pain, often
throughout the body, is reported to result in profound dis-
ability and psychological burden.
Pain treatment in Marfan syndrome is not easy – Nelson
and Speed report low satisfaction with pain treatment
[347,348].
In conclusion, pain assessment must be included in all
consultations for patients with Marfan syndrome. As the pain
is chronic, focus must be on treatment modalities without risk
of addiction. Cognitive therapy, mental and physical activities
and transcutaneous nerve stimulation (TNS) must be
considered.
16.6. Expert opinion on patients’ reported symptoms
(Table 1)
Autism, Asperger syndrome, Attention Deficit Syndrome (ADS)
and Developmental delay are mentioned in the table ‘patients‘
symptoms according to the German Marfan Organization’
(Table 1). These conditions are relatively common in the gen-
eral population. The prevalence of each of them among per-
sons with Marfan syndrome is not known. Larger studies in
persons with clinically and genetically confirmed Marfan syn-
drome must be done. Joint pain is also mentioned in Table 1.
‘Pain’ and ‘chronic pain’, often in more than one body area, is
reported more often by persons with Marfan syndrome than
by persons in the general population. It is difficult to distin-
guish joint pain from musculoskeletal pain caused by other
structures (ligaments, tendons muscles, etc.). The prevalence
of joint pain in Marfan syndrome is unknown.
17. Hemostatic features by Katharina Kornhuber
and Harald Kaemmerer
17.1. Activated fibrinolysis, thrombin and platelet
function
So far, there are only few studies reporting on hemostasis in
patients with Marfan syndrome. Early single case reports pre-
sented Marfan patients with pathological postoperative bleed-
ing disorders [349], as well as thromboembolic events [350,351]
and assumed an association with the inherited disease. Since
then, case-control studies on hemostasis have been performed
in Marfan patients including up to 50 patients. Touat et al.
revealed increased thrombin and platelet activation in Marfan
patients with an aortic diameter above 45 mm, but not below 45
mm [352]. Kornhuber et al. found increased levels of D-dimers in
Marfan patients compared to healthy controls and a correlation
between D-dimers and the diameter of the aortic root [353]. This
is consistent with other studies on thoracic aortic aneurysms of
other etiologies [354,355] and with studies on abdominal aortic
aneurysms [356,357].
Bridges et al. detected increased factor VIII von Willebrand
factor antigen (fVIIIvVVFAg) levels and thrombomodulin levels
in Marfan patients [358]. They postulated that fVIIIvVVFAg
deviations were secondary to endothelial injury caused by
impaired tensile strength of blood vessels and microvascular
damage stimulating the release of fVIIIvVVFAg [358,359]. They
postulated that endothelial injury also results in elevated
thrombomodulin levels [358,359].
17.2. Acquired von Willebrand disease type 2a
Recently, Kornhuber et al. suspected the occurrence of an
acquired von Willebrand syndrome type 2A in a subgroup of
investigated Marfan patients [353]. They assumed that aortic
dilatation and other frequent cardiovascular manifestations of
Marfan syndrome, such as heart valve abnormalities or dysfunc-
tion, could lead to increased shear stress and altered rheology
[360–363], and subsequently to hemostatic changes [352,364].
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Other studies show that an increased shear stress affects the von
Willebrand factor, which becomes more susceptible to pro-
teases, resulting in a dysfunctional interaction with platelets
[365–367]. Such effects have been described in patients with
acquired von Willebrand syndrome type 2a [366,368] and could
also be found in patients with aortic valve stenosis [369–371] or
dysfunctional heart valve prostheses [372].
17.3. Platelet dysfunction
In addition, it is interesting to note that the Ehlers-Danlos
syndrome, another connective tissue disease which may be
accompanied by aortic dilatation, can be associated with pla-
telet dysfunction [373–375]. Platelet dysfunction could be
found in Marfan patients as well, analyzed by the Multiplate
and PFA 100 tests [353].
17.4. Expert opinion on patients’ reported symptoms
(Table 1)
Being asked to list unusual symptoms and complaints noticed
in themselves Marfan patients reported either on recurrent
thrombosis or on coagulation disorders. Both entities encom-
pass a broad spectrum of potential causes but also occur
frequently in the normal population. Whether there is actually
a causal relationship with Marfan syndrome is certainly spec-
ulative, and certainly requires further clarification in the indi-
vidual case. However, our comments indicate that the
literature refers to a causal relationship between Marfan syn-
drome and recurrent thrombosis and coagulation disorders.
This should be taken into account in the long-term care of
affected patients, who often have to undergo surgery.
17.5. Conclusion
Increased fibrinolysis, thrombin, and platelet activation has
been described in Marfan patients, and Marfan syndrome
may be associated with acquired von Willebrand disease
type 2a. The relevance for diagnostic and therapeutic conse-
quences needs further definition.
18. Eye features by Stephan Linke
The role of the precise ocular status in diagnosing and defining
the progression of Marfan syndrome has gained prominence
with the revised Ghent criteria, as the presence of ectopia lentis
with aortic dilation (Z-score ≥2) is currently sufficient to establish
the final diagnosis [16]. In vivo biomechanical dynamic
Scheimpflug-based analyses revealed pathologic corneal defor-
mation in patients with Marfan syndrome having an advanced
systemic score [376]. The potential for ocular abnormalities to
aid in the diagnosis of Marfan syndrome may be much greater
than currently acknowledged due to the aforementioned mod-
ern screening techniques. Investigation of biomechanical and
dynamic changes in tissues that contain abnormal microfibrils is
a reasonable next step in refining the approach to diagnosing
Marfan syndrome and monitor its progression.
18.1. Expert opinion on patients’ reported symptoms
(Table 1)
Patients mention two distinct ophthalmic features that are not
listed as features of Marfan syndrome in the Ghent nosologies,
which we will briefly discuss here:
(1) Early onset cataract as the major symptom from the
patients perspective is interesting and to my opinion
due to the combination of ectopia lentis and cataract.
Both are lens related and result in visual disturbance
(increase of refractive error and optical aberrations by
ectopia lentis) and reduced visual acuity (loss of trans-
parency by early onset cataract). The patient (and doc-
tor) cannot unambiguously differentiate these entities
since both result in reduced visual acuity. Lens replace-
ment (cataract) surgery is the common treatment
option.
(2) Prolonged conjunctival wound healing from the
patients’ perspective is surprising for me and probably
a consequence of retinal detachment surgery. Due to
altered scleral tissue buckling surgery can be more
complex. It would be interesting to correlate the
patient-reported prolonged conjunctival wound heal-
ing to the complexity of the surgery.
19. Discussion
The purpose of this article was to bring the far side of the
Marfan syndrome closer to the awareness of scientists, physi-
cians, and persons who are affected by the disease. We pre-
sent the patients’ perspective together with experts’
systematic mapping of the landscape of the less well-known
features of the Marfan syndrome. Indeed, we came up with an
impressive list of 14 major organ features of Marfan syndrome
that require future scientific and clinical work-up.
After having mapped a landscape, the next task usually is
to check how to make use of the grounds being mapped. To
our view, this condenses down to three questions as listed
below. Rather than profound answers, we only can provide
some evaluative estimates, which we summarize in Figure 1,
and which we comment along briefly in the following:
19.1. Which features are manifestations of Marfan
syndrome?
Which of the 14 major organ features manifest because of
Marfan syndrome, and which occur in Marfan syndrome,
mostly as a consequence of aging, medical therapy, lifestyle,
or because the individual with Marfan syndrome has an addi-
tional, independent disease that origins from other etiologies
than Marfan syndrome [377]?
Defining features of Marfan syndrome that affect the var-
ious organ systems listed are fraught with several issues. First,
it is difficult to separate true manifestations from incidental
occurrences. In many cases, reports of one or a few co-occur-
rences exist, but no studies quantify the prevalence to deter-
mine if these are random events. Second, some features
emerge with age, and since people with Marfan syndrome
have only recently been living to near-normal life
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expectancies, accurate estimates of, say, atrial fibrillation or
diverticulosis will only emerge in years to come. On the other
hand, there is a tendency to report occurrences of common
conditions in young patients with Marfan syndrome. Finally,
reports of the clinical association from more than a decade
ago are complicated by related conditions being lumped with
true Marfan syndrome.
Figure 1 provides our estimation of the degree to which
organ features in Marfan syndrome are caused by the disease
itself, and therefore tend to qualify as manifestations of the
syndrome (Figure 1).
Table 3 shows our evaluative literature analysis and perso-
nal estimate of the existence or strength of association of
clinical features of Marfan syndrome in overlapping clinical
syndromes such as Loeys-Dietz syndrome and vascular
Ehlers-Danlos syndrome (Table 3).
19.2. Which features require change of clinical
management?
Whereas question (i) reflects the etiology of organ features in
Marfan syndrome, question (ii) more pragmatically deals with
the clinical consequences for Marfan care. Which features
require assessment in a baseline evaluation performed in a
Marfan center, which features need regular monitoring once
the diagnosis of Marfan syndrome is established, which fea-
tures should be checked for, only in case of specific symptoms
of complications in Marfan syndrome, and which features may
not play a role in clinical care at all? Figure 1 provides some
evaluative estimates of the clinical consequences of each
organ feature (Figure 1).
19.3. How can we keep in touch with changes of Marfan
syndrome?
Patients change with increases of age, changing lifestyles,
new professional requirements, and new social and envir-
onmental conditions [378]. Medicine also changes with
refined diagnostic modalities, new or modified therapies,
changing medical guidelines, directives, reimbursement
rules, governments, and public fashions. Therefore, the
face of Marfan syndrome will keep on changing, and scien-
tists and physicians should not lock in on a specific picture
of Marfan syndrome simply because they fall in love with
what appears familiar.
Among many ways of keeping in touch with change, we
wish to highlight the importance of listening to our patients.
As is the case in many disorders, there is a discrepancy
between what patients perceive as problems related to their
condition and what is available in the medical literature or
commonly known and looked for by professionals. Although
major advances have already been made in the past decade,
more efforts to empower patients and involve them in both
clinical management and research are needed. To this end,
international networks- and consortia such as the European
Reference Network on Rare multisystemic vascular diseases
(VASCERN) and the GenTAC alliance may offer structured plat-
forms. Indeed, with regard to ERNs, two key drivers have been
identified:, on the one hand, medical experts and scientists
(because of the existing interdependence of research and care
in this highly specialized field) and on the other hand patients
and their families, including the patient organizations [379]. In
the set-up of clinical trials, patient reported outcomes (PRO)
are also increasingly gaining importance [380].
Finally, the broad spectrum of manifestations mentioned in
this work clearly bodes for a multidisciplinary and holistic
approach of the Marfan patient. Ideally, a central physician/
caregiver, aware of the many possible features should coordi-
nate the care and relay to appropriate specialists whenever
needed. The important role of multidisciplinary teams in the
management and treatment of Marfan syndrome has been
described previously [381].
In summary, the data presented in this manuscript provide
an elaborate overview of several clinical features of Marfan
syndrome that are commonly not in the spotlight. Both from a
patient perspective and from a clinical point of view though, a
number of these characteristics certainly deserve more atten-
tion and we hope we have raised awareness for this. Future
research, nosologies, and guidelines may consider some of
these less well-known features of Marfan syndrome.
20. Expert opinion
I. Reviews and guidelines on Marfan syndrome tend to lock in on
the prototypical manifestations of the disease. In this review, we
draw attention to less well-known clinical features that may be
of importance for Marfan patients nevertheless. Based on our
review, we classify these clinical features as follows:
(1) Clinical features that are unlikely to be manifestations of
the Marfan syndrome:
● bicuspid aortic valve
● aneurysm of the cerebral arteries
● cognitive dysfunction
● schizophrenia
(2) Clinical features that are most likely to be considered as
manifestations of Marfan syndrome:
● tricuspid valve prolapse
● cardiomyopathy
● sleep apnea
● vascular disease of the aortic branch vessels
● liver- and kidney cysts
(3) Clinical features that are potential complications of natural
or medical course of Marfan syndrome:
● heart failure
● supraventricular and ventricular arrhythmia
● restrictive lung disease
● spontaneous cerebrospinal fluid leakage
● fatigue
● chronic pain
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II. In addition to these more singular features of Marfan syn-
drome, the image and perception of Marfan syndrome as a
whole appears to transform as well:
● From a disease of the young and slender to a disease of
the old and obese
● From amonogenetic disease of isolated organ system invol-
vement (‘multi-systemic’) to a multifactorial generalized
atherosclerotic and degenerative (‘omni-systemic’) disease
● From isolated aortic disease to a more generalized arter-
ial disease
III. Taking these insights into account, we propose some
recommendations for medical guidelines and clinical care,
such as
● Baseline and follow-up echocardiographic evaluation of
tricuspid aortic valve prolapse and regurgitation
● Baseline and follow-up echocardiographic and N-term-
inal pro-brain natriuretic peptide-based monitoring of
left- and right ventricular function
● Baseline and follow-up 24-h ambulatory electrocardio-
graphy, at least in individuals with symptoms of
arrhythmia
● Baseline and follow-up assessment of pulmonary symp-
toms with the initiation of functional and imaging tests,
following general guidelines of respiratory medicine
● Ambulatory, unattended respiratory polysomnography
screening of sleep apnea may be considered in adults
with Marfan syndrome
● Baseline imaging of abdominal organs for organ cysts
● Baseline and follow-up clinical evaluation for urinary
incontinence in adult women
● Baseline clinical evaluation of muscle strength and risk
factors and symptoms of reduced bone mineral
density
● Baseline dental and orthodontic examination and dental
follow-up
● Baseline and follow-up assessment and documentation
of pain location, severity, and character, careful evalua-
tion of potential causes of pain and symptomatic treat-
ment, where appropriate
IV. However, there are gaps of knowledge, where we observe
the following most urgent needs for prospective, multicenter
clinical studies of the natural history, risk factors and treat-
ment options of
● Myocardial dysfunction and arrhythmia
● Sleep-disordered breathing
● Vascular manifestations
V. On the road to improved care for clinical features of Marfan
patients there are some structural weaknesses to be
overcome:
● Lack of awareness of clinical features of rare disorders
such as Marfan syndrome leading to delayed diagnosis
of the disease
● Economic disparities between countries and regions
obviate access to equal medical care
● Bureaucracy, severe legal regulations including data pro-
tection laws and exaggerated escalation of ethical
requirements prevent multicenter research collaboration
of experts for rare diseases who do not have enough
resources to ensure compliance with the growing bur-
den of legal demands
● Basic researchers tend to cage themselves into an iso-
lated and disconnected world of their labs to stay remote
from patients’ real needs and physicians’ pressing
questions.
● Adequate management of patients and families with
Marfan syndrome necessitates a multidisciplinary and
holistic approach
● Multicenter – patient empowered international colla-
borations between clinicians and researchers should be
encouraged to explore modalities for improved manage-
ment and new targets for tailored treatment
In summary, the data presented in this review translate easily
and quickly into clinical practice. This translation is likely to
improve Marfan care. The review offers numerous clues for
future research, both clinical and basic, that uses as the point
of departure the serious consideration of features of those
individuals who are affected by the Marfan syndrome.
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